EP2440550A1 - Dérivés d'indolamide et composés associés destinés à être utilisés dans le traitement des maladies neurodégénératives - Google Patents
Dérivés d'indolamide et composés associés destinés à être utilisés dans le traitement des maladies neurodégénérativesInfo
- Publication number
- EP2440550A1 EP2440550A1 EP10728150A EP10728150A EP2440550A1 EP 2440550 A1 EP2440550 A1 EP 2440550A1 EP 10728150 A EP10728150 A EP 10728150A EP 10728150 A EP10728150 A EP 10728150A EP 2440550 A1 EP2440550 A1 EP 2440550A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- heterocycle
- alkyl
- alkynyl
- alkenyl
- alkynylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 155
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 32
- 238000011282 treatment Methods 0.000 title claims abstract description 32
- 230000004770 neurodegeneration Effects 0.000 title description 11
- VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical class C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 26
- 230000002265 prevention Effects 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 229910052717 sulfur Inorganic materials 0.000 claims description 526
- 125000000217 alkyl group Chemical group 0.000 claims description 520
- 125000003342 alkenyl group Chemical group 0.000 claims description 486
- 125000000304 alkynyl group Chemical group 0.000 claims description 483
- 125000005842 heteroatom Chemical group 0.000 claims description 425
- 125000000623 heterocyclic group Chemical group 0.000 claims description 365
- -1 arylalkylene Chemical group 0.000 claims description 352
- 125000003118 aryl group Chemical group 0.000 claims description 312
- 125000006270 aryl alkenylene group Chemical group 0.000 claims description 283
- 229910052739 hydrogen Inorganic materials 0.000 claims description 265
- 239000001257 hydrogen Substances 0.000 claims description 265
- 229910052757 nitrogen Inorganic materials 0.000 claims description 264
- 229910052799 carbon Inorganic materials 0.000 claims description 261
- 229910052760 oxygen Inorganic materials 0.000 claims description 247
- 229910052736 halogen Inorganic materials 0.000 claims description 158
- 150000002367 halogens Chemical class 0.000 claims description 158
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 155
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 149
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 129
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 127
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 123
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 115
- 125000004432 carbon atom Chemical group C* 0.000 claims description 62
- 125000004429 atom Chemical group 0.000 claims description 61
- 229910052721 tungsten Inorganic materials 0.000 claims description 59
- 229910052720 vanadium Inorganic materials 0.000 claims description 57
- 150000003839 salts Chemical class 0.000 claims description 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 28
- 125000004122 cyclic group Chemical group 0.000 claims description 27
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 24
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- 239000012453 solvate Substances 0.000 claims description 20
- 125000003386 piperidinyl group Chemical group 0.000 claims description 19
- 229940002612 prodrug Drugs 0.000 claims description 19
- 239000000651 prodrug Substances 0.000 claims description 19
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 17
- 208000024827 Alzheimer disease Diseases 0.000 claims description 14
- 208000018737 Parkinson disease Diseases 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 229910052727 yttrium Inorganic materials 0.000 claims description 8
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims description 7
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 7
- 201000010374 Down Syndrome Diseases 0.000 claims description 7
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 7
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 7
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 7
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 7
- 206010034010 Parkinsonism Diseases 0.000 claims description 7
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 7
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 7
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
- 210000000349 chromosome Anatomy 0.000 claims description 7
- 208000033510 neuroaxonal dystrophy Diseases 0.000 claims description 7
- 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 7
- 230000009529 traumatic brain injury Effects 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 55
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 28
- 108090000185 alpha-Synuclein Proteins 0.000 abstract description 25
- 102000003802 alpha-Synuclein Human genes 0.000 abstract description 23
- 208000034799 Tauopathies Diseases 0.000 abstract description 12
- 208000035475 disorder Diseases 0.000 abstract description 12
- 238000002360 preparation method Methods 0.000 abstract description 8
- 230000003941 amyloidogenesis Effects 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 231100000433 cytotoxic Toxicity 0.000 abstract description 6
- 230000001472 cytotoxic effect Effects 0.000 abstract description 6
- 208000012902 Nervous system disease Diseases 0.000 abstract description 3
- 208000025966 Neurological disease Diseases 0.000 abstract description 3
- 150000001721 carbon Chemical group 0.000 description 120
- 239000000543 intermediate Substances 0.000 description 94
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 83
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 52
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 50
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 49
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 36
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 34
- 239000011734 sodium Substances 0.000 description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 24
- 150000002430 hydrocarbons Chemical group 0.000 description 20
- 150000002148 esters Chemical class 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 101150070547 MAPT gene Proteins 0.000 description 14
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 150000004677 hydrates Chemical class 0.000 description 13
- 229930195733 hydrocarbon Natural products 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 12
- 239000002585 base Substances 0.000 description 11
- 238000009833 condensation Methods 0.000 description 11
- 230000005494 condensation Effects 0.000 description 11
- 125000000842 isoxazolyl group Chemical group 0.000 description 11
- 125000003373 pyrazinyl group Chemical group 0.000 description 11
- 125000000714 pyrimidinyl group Chemical group 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 description 10
- 125000002541 furyl group Chemical group 0.000 description 10
- 125000002883 imidazolyl group Chemical group 0.000 description 10
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 10
- 125000001786 isothiazolyl group Chemical group 0.000 description 10
- 125000003226 pyrazolyl group Chemical group 0.000 description 10
- 125000002098 pyridazinyl group Chemical group 0.000 description 10
- 125000004076 pyridyl group Chemical group 0.000 description 10
- 125000000168 pyrrolyl group Chemical group 0.000 description 10
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 10
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 10
- 125000000335 thiazolyl group Chemical group 0.000 description 10
- 125000001544 thienyl group Chemical group 0.000 description 10
- 125000005986 4-piperidonyl group Chemical group 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 9
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 9
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 9
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 9
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 9
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 9
- 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 9
- 125000003838 furazanyl group Chemical group 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 125000002632 imidazolidinyl group Chemical group 0.000 description 9
- 125000002636 imidazolinyl group Chemical group 0.000 description 9
- 125000004926 indolenyl group Chemical group 0.000 description 9
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 9
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 9
- 125000001041 indolyl group Chemical group 0.000 description 9
- 125000004936 isatinoyl group Chemical group N1(C(=O)C(=O)C2=CC=CC=C12)C(=O)* 0.000 description 9
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 9
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 9
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 9
- 125000002757 morpholinyl group Chemical group 0.000 description 9
- 125000000160 oxazolidinyl group Chemical group 0.000 description 9
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 9
- 125000004193 piperazinyl group Chemical group 0.000 description 9
- 125000005936 piperidyl group Chemical group 0.000 description 9
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 9
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 9
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 9
- 125000002755 pyrazolinyl group Chemical group 0.000 description 9
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 9
- 125000001422 pyrrolinyl group Chemical group 0.000 description 9
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 9
- 102000013498 tau Proteins Human genes 0.000 description 9
- 108010026424 tau Proteins Proteins 0.000 description 9
- 125000003831 tetrazolyl group Chemical group 0.000 description 9
- 125000004306 triazinyl group Chemical group 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 229910001868 water Inorganic materials 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000004215 Carbon black (E152) Substances 0.000 description 7
- 238000004220 aggregation Methods 0.000 description 7
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 6
- 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 6
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 6
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 6
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 6
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 6
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 6
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 6
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 6
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 6
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 6
- 239000003880 polar aprotic solvent Substances 0.000 description 6
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 6
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 6
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 6
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 6
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 6
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 239000000010 aprotic solvent Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000012973 diazabicyclooctane Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 210000005064 dopaminergic neuron Anatomy 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- JXYGLMATGAAIBU-UHFFFAOYSA-N indol-3-ylmethylamine Chemical class C1=CC=C2C(CN)=CNC2=C1 JXYGLMATGAAIBU-UHFFFAOYSA-N 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- 230000009456 molecular mechanism Effects 0.000 description 4
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 125000004932 phenoxathinyl group Chemical group 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000003586 protic polar solvent Substances 0.000 description 4
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000004927 thianaphthalenyl group Chemical group S1C(C=CC2=CC=CC=C12)* 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical group [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 125000004419 alkynylene group Chemical group 0.000 description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 3
- 150000005840 aryl radicals Chemical class 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 125000004404 heteroalkyl group Chemical group 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229940086542 triethylamine Drugs 0.000 description 3
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 2
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 2
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- OOIAXMPVZJKJHK-UHFFFAOYSA-N 3-(1h-indol-3-yl)propan-1-amine Chemical compound C1=CC=C2C(CCCN)=CNC2=C1 OOIAXMPVZJKJHK-UHFFFAOYSA-N 0.000 description 2
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 2
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 2
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 2
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 2
- 125000006043 5-hexenyl group Chemical group 0.000 description 2
- FEJUGLKDZJDVFY-UHFFFAOYSA-N 9-borabicyclo(3.3.1)nonane Chemical compound C1CCC2CCCC1B2 FEJUGLKDZJDVFY-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- 125000004069 aziridinyl group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- YSHOWEKUVWPFNR-UHFFFAOYSA-N burgess reagent Chemical compound CC[N+](CC)(CC)S(=O)(=O)N=C([O-])OC YSHOWEKUVWPFNR-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical group C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical group C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- DLTWRJKNDVIIHL-UHFFFAOYSA-N n-[2-(5-chloro-2-methyl-1h-indol-3-yl)ethyl]-1-(oxolan-2-ylmethyl)triazole-4-carboxamide Chemical compound CC=1NC2=CC=C(Cl)C=C2C=1CCNC(=O)C(N=N1)=CN1CC1CCCO1 DLTWRJKNDVIIHL-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000006950 reactive oxygen species formation Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229930192474 thiophene Chemical group 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 2
- OHFFCTBNVLBDGQ-GOSISDBHSA-N (3r)-1-benzyl-n-[2-(5-chloro-1h-indol-3-yl)ethyl]pyrrolidine-3-carboxamide Chemical compound C([C@H](C1)C(=O)NCCC2=CNC3=CC=C(C=C32)Cl)CN1CC1=CC=CC=C1 OHFFCTBNVLBDGQ-GOSISDBHSA-N 0.000 description 1
- OHFFCTBNVLBDGQ-SFHVURJKSA-N (3s)-1-benzyl-n-[2-(5-chloro-1h-indol-3-yl)ethyl]pyrrolidine-3-carboxamide Chemical compound C([C@@H](C1)C(=O)NCCC2=CNC3=CC=C(C=C32)Cl)CN1CC1=CC=CC=C1 OHFFCTBNVLBDGQ-SFHVURJKSA-N 0.000 description 1
- CLLGNSQTFDRNBE-QGZVFWFLSA-N (4r)-4-benzyl-n-[2-(5-chloro-1h-indol-3-yl)ethyl]-4,5-dihydro-1,3-oxazole-2-carboxamide Chemical compound C([C@H]1N=C(OC1)C(=O)NCCC1=CNC2=CC=C(C=C21)Cl)C1=CC=CC=C1 CLLGNSQTFDRNBE-QGZVFWFLSA-N 0.000 description 1
- DAXFXOKIDFTTEO-SFHVURJKSA-N (4r)-n-[2-(5-chloro-1h-indol-3-yl)ethyl]-4-cyclohexyl-4,5-dihydro-1,3-oxazole-2-carboxamide Chemical compound C1([C@H]2N=C(OC2)C(=O)NCCC2=CNC3=CC=C(C=C32)Cl)CCCCC1 DAXFXOKIDFTTEO-SFHVURJKSA-N 0.000 description 1
- CLLGNSQTFDRNBE-KRWDZBQOSA-N (4s)-4-benzyl-n-[2-(5-chloro-1h-indol-3-yl)ethyl]-4,5-dihydro-1,3-oxazole-2-carboxamide Chemical compound C([C@@H]1N=C(OC1)C(=O)NCCC1=CNC2=CC=C(C=C21)Cl)C1=CC=CC=C1 CLLGNSQTFDRNBE-KRWDZBQOSA-N 0.000 description 1
- DAXFXOKIDFTTEO-GOSISDBHSA-N (4s)-n-[2-(5-chloro-1h-indol-3-yl)ethyl]-4-cyclohexyl-4,5-dihydro-1,3-oxazole-2-carboxamide Chemical compound C1([C@@H]2N=C(OC2)C(=O)NCCC2=CNC3=CC=C(C=C32)Cl)CCCCC1 DAXFXOKIDFTTEO-GOSISDBHSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- AIGGHUHRMKRVJY-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-n-[2-(1h-indol-3-yl)ethyl]-5-oxopyrrolidine-3-carboxamide Chemical compound O1CCOC2=CC(N3CC(CC3=O)C(NCCC=3C4=CC=CC=C4NC=3)=O)=CC=C21 AIGGHUHRMKRVJY-UHFFFAOYSA-N 0.000 description 1
- UNZWMVNOGXXOLS-UHFFFAOYSA-N 1-(3-benzylimidazolidin-1-yl)-3-(5-chloro-1h-indol-3-yl)propan-1-one Chemical compound C12=CC(Cl)=CC=C2NC=C1CCC(=O)N(C1)CCN1CC1=CC=CC=C1 UNZWMVNOGXXOLS-UHFFFAOYSA-N 0.000 description 1
- IZGBKGXNROBYMB-UHFFFAOYSA-N 1-(4-acetylphenyl)-n-[2-(5-chloro-1h-indol-3-yl)ethyl]-2-oxopyrrolidine-3-carboxamide Chemical compound C1=CC(C(=O)C)=CC=C1N1C(=O)C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 IZGBKGXNROBYMB-UHFFFAOYSA-N 0.000 description 1
- HHDSXPFBRILDEP-UHFFFAOYSA-N 1-(4-chloro-3-fluorophenyl)-n-[2-(5-chloro-1h-indol-3-yl)ethyl]-2-oxopyrrolidine-3-carboxamide Chemical compound C1=C(Cl)C(F)=CC(N2C(C(C(=O)NCCC=3C4=CC(Cl)=CC=C4NC=3)CC2)=O)=C1 HHDSXPFBRILDEP-UHFFFAOYSA-N 0.000 description 1
- HNRLRFAGUJWXLZ-UHFFFAOYSA-N 1-(4-ethylphenyl)-n-[2-(5-methyl-1h-indol-3-yl)ethyl]-2-oxopyrrolidine-3-carboxamide Chemical compound C1=CC(CC)=CC=C1N1C(=O)C(C(=O)NCCC=2C3=CC(C)=CC=C3NC=2)CC1 HNRLRFAGUJWXLZ-UHFFFAOYSA-N 0.000 description 1
- SYUVOCPBLNIUAV-UHFFFAOYSA-N 1-(furan-2-ylmethyl)-n-[2-(1h-indol-3-yl)ethyl]-5-oxopyrrolidine-3-carboxamide Chemical compound C=1NC2=CC=CC=C2C=1CCNC(=O)C(CC1=O)CN1CC1=CC=CO1 SYUVOCPBLNIUAV-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- DZTRMDZJPAQJOX-UHFFFAOYSA-N 1-[(2-chlorophenyl)methyl]-n-[2-(1h-indol-3-yl)ethyl]-5-oxopyrrolidine-3-carboxamide Chemical compound ClC1=CC=CC=C1CN1C(=O)CC(C(=O)NCCC=2C3=CC=CC=C3NC=2)C1 DZTRMDZJPAQJOX-UHFFFAOYSA-N 0.000 description 1
- NPKZRYNQPKWQKR-UHFFFAOYSA-N 1-[4-(diethylsulfamoyl)phenyl]-n-[2-(1h-indol-3-yl)ethyl]-5-oxopyrrolidine-3-carboxamide Chemical compound C1=CC(S(=O)(=O)N(CC)CC)=CC=C1N1C(=O)CC(C(=O)NCCC=2C3=CC=CC=C3NC=2)C1 NPKZRYNQPKWQKR-UHFFFAOYSA-N 0.000 description 1
- MBZAQYYGAYYUBI-UHFFFAOYSA-N 1-benzyl-n-[2-(1h-indol-3-yl)ethyl]-5-oxopyrrolidine-3-carboxamide Chemical compound C=1NC2=CC=CC=C2C=1CCNC(=O)C(CC1=O)CN1CC1=CC=CC=C1 MBZAQYYGAYYUBI-UHFFFAOYSA-N 0.000 description 1
- HPGYYCHDHCWIKV-UHFFFAOYSA-N 1-benzyl-n-[2-(5-chloro-1h-indol-3-yl)ethyl]-2-oxopyrrolidine-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(C1=O)CCN1CC1=CC=CC=C1 HPGYYCHDHCWIKV-UHFFFAOYSA-N 0.000 description 1
- XBINDIIYILQSJB-UHFFFAOYSA-N 1-benzyl-n-[2-(5-chloro-1h-indol-3-yl)ethyl]triazole-4-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(N=N1)=CN1CC1=CC=CC=C1 XBINDIIYILQSJB-UHFFFAOYSA-N 0.000 description 1
- MUXBHXBDEFJJQK-UHFFFAOYSA-N 1-borabicyclo[3.3.1]nonane Chemical compound C1CCC2CCCB1C2 MUXBHXBDEFJJQK-UHFFFAOYSA-N 0.000 description 1
- BLNKEEUWKKROEX-UHFFFAOYSA-N 1-cyclopropyl-n-[2-(1h-indol-3-yl)ethyl]-2,5-dimethylpyrrole-3-carboxamide Chemical compound CC1=CC(C(=O)NCCC=2C3=CC=CC=C3NC=2)=C(C)N1C1CC1 BLNKEEUWKKROEX-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1h-pyrazole Chemical group C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 description 1
- FFMBYMANYCDCMK-UHFFFAOYSA-N 2,5-dihydro-1h-imidazole Chemical group C1NCN=C1 FFMBYMANYCDCMK-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical group CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- YOYVZBPYRISIIW-UHFFFAOYSA-N 2-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]-3h-1,2,4-oxadiazole Chemical compound C1=CC=C(C(F)(F)F)C(F)=C1CC(O1)=NCN1CCC1=CNC2=CC=C(Cl)C=C12 YOYVZBPYRISIIW-UHFFFAOYSA-N 0.000 description 1
- YHGHUQNGBZBYDR-UHFFFAOYSA-N 2-benzyl-5-tert-butyl-n-[2-(5-chloro-1h-indol-3-yl)ethyl]pyrazole-3-carboxamide Chemical compound N1=C(C(C)(C)C)C=C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)N1CC1=CC=CC=C1 YHGHUQNGBZBYDR-UHFFFAOYSA-N 0.000 description 1
- KRTGJZMJJVEKRX-UHFFFAOYSA-N 2-phenylethan-1-yl Chemical group [CH2]CC1=CC=CC=C1 KRTGJZMJJVEKRX-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical group C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- WLDJEXJYZOOSRJ-UHFFFAOYSA-N 3-benzyl-n-[2-(5-chloro-1h-indol-3-yl)ethyl]imidazolidine-1-carboxamide;n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(4-chlorophenyl)-2-(trifluoromethyl)furan-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)N(C1)CCN1CC1=CC=CC=C1.C=1C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C(C(F)(F)F)OC=1C1=CC=C(Cl)C=C1 WLDJEXJYZOOSRJ-UHFFFAOYSA-N 0.000 description 1
- SOXAIIZPOSZSAX-UHFFFAOYSA-N 3-benzyl-n-[2-(5-chloro-1h-indol-3-yl)ethyl]pyrrolidine-1-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)N(C1)CCC1CC1=CC=CC=C1 SOXAIIZPOSZSAX-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical group C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical group C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- LREWIESLSXKEKK-UHFFFAOYSA-N 5-[(2,5-difluorophenyl)methyl]-n-[2-(2h-indazol-3-yl)ethyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=C(F)C(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC=CC=C3NN=2)=C1 LREWIESLSXKEKK-UHFFFAOYSA-N 0.000 description 1
- KABJVOPHTHWTDB-UHFFFAOYSA-N 5-[(2,5-difluorophenyl)methyl]-n-[2-(5-phenyl-1h-indol-3-yl)ethyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=C(F)C(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC(=CC=C3NC=2)C=2C=CC=CC=2)=C1 KABJVOPHTHWTDB-UHFFFAOYSA-N 0.000 description 1
- QQEBIMKQOZLPPE-UHFFFAOYSA-N 5-[(2,5-difluorophenyl)methyl]-n-[2-[5-(trifluoromethyl)-1h-indol-3-yl]ethyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=C(F)C(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC(=CC=C3NC=2)C(F)(F)F)=C1 QQEBIMKQOZLPPE-UHFFFAOYSA-N 0.000 description 1
- ZPNVLUBGKAYWKH-UHFFFAOYSA-N 5-[(3-fluorophenyl)methyl]-n-[2-(1h-indol-3-yl)ethyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=CC(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC=CC=C3NC=2)=C1 ZPNVLUBGKAYWKH-UHFFFAOYSA-N 0.000 description 1
- ANNVIKOGEISNCO-UHFFFAOYSA-N 5-[(3-fluorophenyl)methyl]-n-[2-(5-methoxy-1h-indol-3-yl)ethyl]-1,2-oxazole-3-carboxamide Chemical compound C12=CC(OC)=CC=C2NC=C1CCNC(=O)C(=NO1)C=C1CC1=CC=CC(F)=C1 ANNVIKOGEISNCO-UHFFFAOYSA-N 0.000 description 1
- WITAPCIPZAVJQS-UHFFFAOYSA-N 5-[(3-fluorophenyl)methyl]-n-[2-(5-methyl-1h-indol-3-yl)ethyl]-1,2-oxazole-3-carboxamide Chemical compound C12=CC(C)=CC=C2NC=C1CCNC(=O)C(=NO1)C=C1CC1=CC=CC(F)=C1 WITAPCIPZAVJQS-UHFFFAOYSA-N 0.000 description 1
- OIRFFECAPCJTHG-UHFFFAOYSA-N 5-[(3-fluorophenyl)methyl]-n-[2-(6-methoxy-1h-indol-3-yl)ethyl]-1,2-oxazole-3-carboxamide Chemical compound C=1NC2=CC(OC)=CC=C2C=1CCNC(=O)C(=NO1)C=C1CC1=CC=CC(F)=C1 OIRFFECAPCJTHG-UHFFFAOYSA-N 0.000 description 1
- DJDBSMIGXRKSNA-UHFFFAOYSA-N 5-[(4-chloro-3-fluorophenyl)methyl]-n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound C1=C(Cl)C(F)=CC(CC=2ON=C(N=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1 DJDBSMIGXRKSNA-UHFFFAOYSA-N 0.000 description 1
- LAUOYCJYVDHIAV-UHFFFAOYSA-N 5-[(4-tert-butylphenyl)methyl]-n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1CC1=NC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 LAUOYCJYVDHIAV-UHFFFAOYSA-N 0.000 description 1
- YKGIDKHWJVQQBP-UHFFFAOYSA-N 5-amino-n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1,2-oxazole-3-carboxamide Chemical compound O1C(N)=CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=N1 YKGIDKHWJVQQBP-UHFFFAOYSA-N 0.000 description 1
- AEQJBLFROTZTGM-UHFFFAOYSA-N 5-benzyl-n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(N=1)=NOC=1CC1=CC=CC=C1 AEQJBLFROTZTGM-UHFFFAOYSA-N 0.000 description 1
- AXDCCVORQCCYLJ-UHFFFAOYSA-N 5-benzyl-n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1,2,4-thiadiazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(N=1)=NSC=1CC1=CC=CC=C1 AXDCCVORQCCYLJ-UHFFFAOYSA-N 0.000 description 1
- GDVGQEPTKFWLHX-UHFFFAOYSA-N 5-benzyl-n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(=NO1)C=C1CC1=CC=CC=C1 GDVGQEPTKFWLHX-UHFFFAOYSA-N 0.000 description 1
- RXOTWHVWTYHMJK-UHFFFAOYSA-N 5-benzyl-n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1,2-thiazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(=NS1)C=C1CC1=CC=CC=C1 RXOTWHVWTYHMJK-UHFFFAOYSA-N 0.000 description 1
- NWLMTCBBGMETEW-UHFFFAOYSA-N 5-benzyl-n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1,3,4-oxadiazole-2-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(O1)=NN=C1CC1=CC=CC=C1 NWLMTCBBGMETEW-UHFFFAOYSA-N 0.000 description 1
- CJOCMSBNXDDIJE-UHFFFAOYSA-N 5-benzyl-n-[2-(5-chloro-1h-indol-3-yl)ethyl]-4,5-dihydro-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(C1)=NOC1CC1=CC=CC=C1 CJOCMSBNXDDIJE-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical group C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 208000011644 Neurologic Gait disease Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- 206010071390 Resting tremor Diseases 0.000 description 1
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 102000019355 Synuclein Human genes 0.000 description 1
- 108050006783 Synuclein Proteins 0.000 description 1
- 241000611306 Taeniopygia guttata Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- WOBMYKAWTNZMNA-UHFFFAOYSA-N [4-(5-chloro-1h-indol-3-yl)piperidin-1-yl]-[5-[(2,5-difluorophenyl)methyl]-1,2-oxazol-3-yl]methanone Chemical compound FC1=CC=C(F)C(CC=2ON=C(C=2)C(=O)N2CCC(CC2)C=2C3=CC(Cl)=CC=C3NC=2)=C1 WOBMYKAWTNZMNA-UHFFFAOYSA-N 0.000 description 1
- FAYFEQUVGIFYQF-UHFFFAOYSA-N [5-[(2,5-difluorophenyl)methyl]-1,2-oxazol-3-yl]-[4-(1h-indol-3-yl)piperidin-1-yl]methanone Chemical compound FC1=CC=C(F)C(CC=2ON=C(C=2)C(=O)N2CCC(CC2)C=2C3=CC=CC=C3NC=2)=C1 FAYFEQUVGIFYQF-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- 125000005133 alkynyloxy group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- AAFFTDXPYADISO-UHFFFAOYSA-N cyclohexyne Chemical compound C1CCC#CC1 AAFFTDXPYADISO-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000004474 heteroalkylene group Chemical group 0.000 description 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005312 heteroarylalkynyl group Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical group C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000003951 lactams Chemical group 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003924 mental process Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- IDVOXGDHQGXSOR-UHFFFAOYSA-N n-[(5-chloro-1h-indol-3-yl)methyl]-5-[(3-fluorophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=CC(CC=2ON=C(C=2)C(=O)NCC=2C3=CC(Cl)=CC=C3NC=2)=C1 IDVOXGDHQGXSOR-UHFFFAOYSA-N 0.000 description 1
- IZQMKWHXYVELKU-UHFFFAOYSA-N n-[2-(1-benzofuran-3-yl)ethyl]-5-[(3-fluorophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=CC(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC=CC=C3OC=2)=C1 IZQMKWHXYVELKU-UHFFFAOYSA-N 0.000 description 1
- HESZFYPOBZZCIU-UHFFFAOYSA-N n-[2-(1h-indol-3-yl)ethyl]-1-naphthalen-1-yl-5-oxopyrrolidine-3-carboxamide Chemical compound C1=CC=C2C(N3CC(CC3=O)C(NCCC=3C4=CC=CC=C4NC=3)=O)=CC=CC2=C1 HESZFYPOBZZCIU-UHFFFAOYSA-N 0.000 description 1
- MYILEIWJGYMBTF-UHFFFAOYSA-N n-[2-(1h-indol-3-yl)ethyl]-2-(4-methylanilino)-1,3-thiazole-4-carboxamide Chemical compound C1=CC(C)=CC=C1NC1=NC(C(=O)NCCC=2C3=CC=CC=C3NC=2)=CS1 MYILEIWJGYMBTF-UHFFFAOYSA-N 0.000 description 1
- ASESIXNXCYOHFE-UHFFFAOYSA-N n-[2-(1h-indol-3-yl)ethyl]-4-methyl-2-(2-phenylethylamino)-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NCCC=2C3=CC=CC=C3NC=2)=C(C)N=C1NCCC1=CC=CC=C1 ASESIXNXCYOHFE-UHFFFAOYSA-N 0.000 description 1
- XEWOFKIODLMWPW-UHFFFAOYSA-N n-[2-(1h-indol-3-yl)ethyl]-4-methyl-2-(2-propylpyridin-4-yl)-1,3-thiazole-5-carboxamide Chemical compound C1=NC(CCC)=CC(C=2SC(=C(C)N=2)C(=O)NCCC=2C3=CC=CC=C3NC=2)=C1 XEWOFKIODLMWPW-UHFFFAOYSA-N 0.000 description 1
- KPTBXHDVJYQOIF-UHFFFAOYSA-N n-[2-(1h-indol-3-yl)ethyl]-4-methyl-2-(4-methylphenyl)-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NCCC=2C3=CC=CC=C3NC=2)=C(C)N=C1C1=CC=C(C)C=C1 KPTBXHDVJYQOIF-UHFFFAOYSA-N 0.000 description 1
- OMXFXWODUXJKKX-UHFFFAOYSA-N n-[2-(1h-indol-3-yl)ethyl]-5-oxo-1-(1-phenylethyl)pyrrolidine-3-carboxamide Chemical compound C1C(C(=O)NCCC=2C3=CC=CC=C3NC=2)CC(=O)N1C(C)C1=CC=CC=C1 OMXFXWODUXJKKX-UHFFFAOYSA-N 0.000 description 1
- JXHNQXBXFPWHQY-UHFFFAOYSA-N n-[2-(5-bromo-1h-indol-3-yl)ethyl]-5-[(2,5-difluorophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=C(F)C(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC(Br)=CC=C3NC=2)=C1 JXHNQXBXFPWHQY-UHFFFAOYSA-N 0.000 description 1
- HOJAQQUGJDQIGH-UHFFFAOYSA-N n-[2-(5-chloro-1-methylindol-3-yl)ethyl]-5-[(3-fluorophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2N(C)C=C1CCNC(=O)C(=NO1)C=C1CC1=CC=CC(F)=C1 HOJAQQUGJDQIGH-UHFFFAOYSA-N 0.000 description 1
- CXIQZDWKJYTPEX-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1,3-oxazole-5-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C1=CN=CO1 CXIQZDWKJYTPEX-UHFFFAOYSA-N 0.000 description 1
- QLGJTYBYPHTZFE-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(1,3-dihydro-2-benzofuran-5-yl)-2-oxopyrrolidine-3-carboxamide Chemical compound C1=C2COCC2=CC(N2CCC(C2=O)C(=O)NCCC2=CNC3=CC=C(C=C32)Cl)=C1 QLGJTYBYPHTZFE-UHFFFAOYSA-N 0.000 description 1
- JPOIATMYRBPUAE-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(1-methylindol-5-yl)-2-oxopyrrolidine-3-carboxamide Chemical compound C1=C(Cl)C=C2C(CCNC(=O)C3CCN(C3=O)C=3C=C4C=CN(C4=CC=3)C)=CNC2=C1 JPOIATMYRBPUAE-UHFFFAOYSA-N 0.000 description 1
- NQCMJHZXHNGCMN-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(1-methylpyrazol-3-yl)-2-oxopyrrolidine-3-carboxamide Chemical compound CN1C=CC(N2C(C(C(=O)NCCC=3C4=CC(Cl)=CC=C4NC=3)CC2)=O)=N1 NQCMJHZXHNGCMN-UHFFFAOYSA-N 0.000 description 1
- ISXPPYLXWUKXHF-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(2,3-dihydro-1h-inden-5-yl)-2-oxopyrrolidine-3-carboxamide Chemical compound C1=C2CCCC2=CC(N2CCC(C2=O)C(=O)NCCC2=CNC3=CC=C(C=C32)Cl)=C1 ISXPPYLXWUKXHF-UHFFFAOYSA-N 0.000 description 1
- BLPLJOQPZWFAQV-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(2,6-difluorophenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound FC1=CC=CC(F)=C1N1C(=O)C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 BLPLJOQPZWFAQV-UHFFFAOYSA-N 0.000 description 1
- JZPXIRIOIMMSLB-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(2-chlorophenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(C1=O)CCN1C1=CC=CC=C1Cl JZPXIRIOIMMSLB-UHFFFAOYSA-N 0.000 description 1
- IURITWOYMPETSD-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(2-ethylphenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound CCC1=CC=CC=C1N1C(=O)C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 IURITWOYMPETSD-UHFFFAOYSA-N 0.000 description 1
- NJQSFAVMWGXGJU-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(2-fluorophenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound FC1=CC=CC=C1N1C(=O)C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 NJQSFAVMWGXGJU-UHFFFAOYSA-N 0.000 description 1
- GOZYQVZPAAWRFR-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(2-methoxyphenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound COC1=CC=CC=C1N1C(=O)C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 GOZYQVZPAAWRFR-UHFFFAOYSA-N 0.000 description 1
- BQFFNBCQSHWLIL-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(2-methylphenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound CC1=CC=CC=C1N1C(=O)C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 BQFFNBCQSHWLIL-UHFFFAOYSA-N 0.000 description 1
- HQGCUKJQSMDHSJ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(3,4-difluorophenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1N1C(=O)C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 HQGCUKJQSMDHSJ-UHFFFAOYSA-N 0.000 description 1
- HYFXXKMJJUJKEI-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(3,4-dimethylphenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound C1=C(C)C(C)=CC=C1N1C(=O)C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 HYFXXKMJJUJKEI-UHFFFAOYSA-N 0.000 description 1
- KMKIFZXQPZOYDH-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(3,5-difluorophenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound FC1=CC(F)=CC(N2C(C(C(=O)NCCC=3C4=CC(Cl)=CC=C4NC=3)CC2)=O)=C1 KMKIFZXQPZOYDH-UHFFFAOYSA-N 0.000 description 1
- WQVXGZGGQHZDJO-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(3-chlorophenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound ClC1=CC=CC(N2C(C(C(=O)NCCC=3C4=CC(Cl)=CC=C4NC=3)CC2)=O)=C1 WQVXGZGGQHZDJO-UHFFFAOYSA-N 0.000 description 1
- SMFZTIQLLRTGRK-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(3-ethylphenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound CCC1=CC=CC(N2C(C(C(=O)NCCC=3C4=CC(Cl)=CC=C4NC=3)CC2)=O)=C1 SMFZTIQLLRTGRK-UHFFFAOYSA-N 0.000 description 1
- NAZXHTWJDAZOSH-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(3-fluoro-4-methoxyphenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound C1=C(F)C(OC)=CC=C1N1C(=O)C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 NAZXHTWJDAZOSH-UHFFFAOYSA-N 0.000 description 1
- RSNXGMYGXCVRBS-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(3-fluoro-4-methylphenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound C1=C(F)C(C)=CC=C1N1C(=O)C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 RSNXGMYGXCVRBS-UHFFFAOYSA-N 0.000 description 1
- MHSKJRMUWRHUGT-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(3-fluorophenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound FC1=CC=CC(N2C(C(C(=O)NCCC=3C4=CC(Cl)=CC=C4NC=3)CC2)=O)=C1 MHSKJRMUWRHUGT-UHFFFAOYSA-N 0.000 description 1
- PIPIXCVOYWZLID-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(3-methoxyphenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound COC1=CC=CC(N2C(C(C(=O)NCCC=3C4=CC(Cl)=CC=C4NC=3)CC2)=O)=C1 PIPIXCVOYWZLID-UHFFFAOYSA-N 0.000 description 1
- GZNLPZKYRLQTBC-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(3-methylphenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound CC1=CC=CC(N2C(C(C(=O)NCCC=3C4=CC(Cl)=CC=C4NC=3)CC2)=O)=C1 GZNLPZKYRLQTBC-UHFFFAOYSA-N 0.000 description 1
- SEYBNZXNFSKRRC-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(4-chlorophenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(=O)C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 SEYBNZXNFSKRRC-UHFFFAOYSA-N 0.000 description 1
- RETIDGBCSJYDFT-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(4-cyanophenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(C1=O)CCN1C1=CC=C(C#N)C=C1 RETIDGBCSJYDFT-UHFFFAOYSA-N 0.000 description 1
- LRXHIHFJMAWSAJ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(4-ethylphenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound C1=CC(CC)=CC=C1N1C(=O)C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 LRXHIHFJMAWSAJ-UHFFFAOYSA-N 0.000 description 1
- YOHFYDPIIPQVIE-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(4-fluorophenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound C1=CC(F)=CC=C1N1C(=O)C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 YOHFYDPIIPQVIE-UHFFFAOYSA-N 0.000 description 1
- LUWDQJBFXCTSNA-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(4-methoxyphenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 LUWDQJBFXCTSNA-UHFFFAOYSA-N 0.000 description 1
- WTERGZZKEHWSGE-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(4-methylphenyl)-2-oxopyrrolidine-3-carboxamide Chemical compound C1=CC(C)=CC=C1N1C(=O)C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 WTERGZZKEHWSGE-UHFFFAOYSA-N 0.000 description 1
- KBPKSNJFJWUZMW-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(4-methylphenyl)pyrrolidine-3-carboxamide Chemical compound C1=CC(C)=CC=C1N1CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 KBPKSNJFJWUZMW-UHFFFAOYSA-N 0.000 description 1
- YDPJPCHQWHTMAX-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-(cyclohexylmethyl)-2-oxopyrrolidine-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(C1=O)CCN1CC1CCCCC1 YDPJPCHQWHTMAX-UHFFFAOYSA-N 0.000 description 1
- KMTPBFKMMMLMNV-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-cyclohexyl-2-oxopyrrolidine-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(C1=O)CCN1C1CCCCC1 KMTPBFKMMMLMNV-UHFFFAOYSA-N 0.000 description 1
- SYPLWSWLQHEZPG-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(CC1=O)CN1C1CCCCC1 SYPLWSWLQHEZPG-UHFFFAOYSA-N 0.000 description 1
- TYXGKYIGUWCPRP-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-cyclohexyltriazole-4-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(N=N1)=CN1C1CCCCC1 TYXGKYIGUWCPRP-UHFFFAOYSA-N 0.000 description 1
- VCGYMOACPVXNDJ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-cyclopropyl-2-oxopyrrolidine-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(C1=O)CCN1C1CC1 VCGYMOACPVXNDJ-UHFFFAOYSA-N 0.000 description 1
- ZDOIMXBENZTKEH-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-methyl-5-phenylpyrazole-3-carboxamide Chemical compound CN1N=C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)C=C1C1=CC=CC=C1 ZDOIMXBENZTKEH-UHFFFAOYSA-N 0.000 description 1
- IARAAZAGJCXJCC-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-methyl-5-thiophen-2-ylpyrazole-3-carboxamide Chemical compound CN1N=C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)C=C1C1=CC=CS1 IARAAZAGJCXJCC-UHFFFAOYSA-N 0.000 description 1
- FKUUMMYPHKEVPF-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-methylpyrazole-3-carboxamide Chemical compound CN1C=CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=N1 FKUUMMYPHKEVPF-UHFFFAOYSA-N 0.000 description 1
- XBTKYILRQNFQIW-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-phenylpyrrolidine-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(C1)CCN1C1=CC=CC=C1 XBTKYILRQNFQIW-UHFFFAOYSA-N 0.000 description 1
- UUJHPGRXAIEAHJ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-1-phenyltriazole-4-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(N=N1)=CN1C1=CC=CC=C1 UUJHPGRXAIEAHJ-UHFFFAOYSA-N 0.000 description 1
- AHUUUNCMJPHVIT-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-2-methylpyrazole-3-carboxamide Chemical compound CN1N=CC=C1C(=O)NCCC1=CNC2=CC=C(Cl)C=C12 AHUUUNCMJPHVIT-UHFFFAOYSA-N 0.000 description 1
- HQAITGONYADBMQ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-2-oxo-1-(3-pyrrol-1-ylphenyl)pyrrolidine-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(C1=O)CCN1C(C=1)=CC=CC=1N1C=CC=C1 HQAITGONYADBMQ-UHFFFAOYSA-N 0.000 description 1
- PBVDUQSMJORJTP-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-2-oxo-1-(4-propan-2-ylphenyl)pyrrolidine-3-carboxamide Chemical compound C1=CC(C(C)C)=CC=C1N1C(=O)C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 PBVDUQSMJORJTP-UHFFFAOYSA-N 0.000 description 1
- DKFIYPHBGJWKEL-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-2-oxo-1-[4-(trifluoromethoxy)phenyl]pyrrolidine-3-carboxamide Chemical compound C1=CC(OC(F)(F)F)=CC=C1N1C(=O)C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 DKFIYPHBGJWKEL-UHFFFAOYSA-N 0.000 description 1
- PJCFXYKZDQTFML-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-2-oxo-1-[4-(trifluoromethyl)phenyl]pyrrolidine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1N1C(=O)C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)CC1 PJCFXYKZDQTFML-UHFFFAOYSA-N 0.000 description 1
- JBYNLONIZGIDPP-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-2-oxo-1-phenylpyrrolidine-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(C1=O)CCN1C1=CC=CC=C1 JBYNLONIZGIDPP-UHFFFAOYSA-N 0.000 description 1
- KAYNTORSYJVPTJ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-2-phenyl-1,3-oxazole-5-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(O1)=CN=C1C1=CC=CC=C1 KAYNTORSYJVPTJ-UHFFFAOYSA-N 0.000 description 1
- CVEGSNAMUPNNQJ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-2-phenyl-1,3-thiazole-4-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(N=1)=CSC=1C1=CC=CC=C1 CVEGSNAMUPNNQJ-UHFFFAOYSA-N 0.000 description 1
- SZZRCAUITIKIDR-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-2-phenylpyrazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C1=CC=NN1C1=CC=CC=C1 SZZRCAUITIKIDR-UHFFFAOYSA-N 0.000 description 1
- QSUPQURKSOSXII-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-3-methyl-5-phenyl-1,2-oxazole-4-carboxamide Chemical compound C=1NC2=CC=C(Cl)C=C2C=1CCNC(=O)C=1C(C)=NOC=1C1=CC=CC=C1 QSUPQURKSOSXII-UHFFFAOYSA-N 0.000 description 1
- ICSTVOBHINCEOR-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-3-phenyl-1,2-oxazole-5-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(ON=1)=CC=1C1=CC=CC=C1 ICSTVOBHINCEOR-UHFFFAOYSA-N 0.000 description 1
- JIJIVOQMVJRTFO-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-3-phenyl-4,5-dihydro-1,2-oxazole-5-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(ON=1)CC=1C1=CC=CC=C1 JIJIVOQMVJRTFO-UHFFFAOYSA-N 0.000 description 1
- MRDHSOZZLILLJQ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-3-phenylpyrrolidine-1-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)N(C1)CCC1C1=CC=CC=C1 MRDHSOZZLILLJQ-UHFFFAOYSA-N 0.000 description 1
- UCPVLHXXTIFAGL-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-4-methyl-1,3-oxazole-5-carboxamide Chemical compound N1=COC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1C UCPVLHXXTIFAGL-UHFFFAOYSA-N 0.000 description 1
- OVHLCONILZQLCX-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-4-methyl-2-(4-methylphenyl)-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C(C)N=C1C1=CC=C(C)C=C1 OVHLCONILZQLCX-UHFFFAOYSA-N 0.000 description 1
- ANFTVGURQYESMQ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-4-methyl-2-phenyl-1,3-oxazole-5-carboxamide Chemical compound O1C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C(C)N=C1C1=CC=CC=C1 ANFTVGURQYESMQ-UHFFFAOYSA-N 0.000 description 1
- NBFJGNZIXKVBKD-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-4-methyl-2-phenyl-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C(C)N=C1C1=CC=CC=C1 NBFJGNZIXKVBKD-UHFFFAOYSA-N 0.000 description 1
- RRJSWDJKMBOBBU-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-4-methyl-2-pyrazin-2-yl-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C(C)N=C1C1=CN=CC=N1 RRJSWDJKMBOBBU-UHFFFAOYSA-N 0.000 description 1
- YKLKUSHVDZGFKB-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-4-phenyl-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C1=NOC=C1C1=CC=CC=C1 YKLKUSHVDZGFKB-UHFFFAOYSA-N 0.000 description 1
- ACOHQTZGFLWHKM-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-4-phenyl-4,5-dihydro-1,3-oxazole-2-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(OC1)=NC1C1=CC=CC=C1 ACOHQTZGFLWHKM-UHFFFAOYSA-N 0.000 description 1
- SYGNEIOTGIUEDM-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(2,3-dihydro-1,4-benzodioxin-5-yl)-1,2-oxazole-3-carboxamide Chemical compound O1CCOC2=C1C=CC=C2C1=CC(C(=O)NCCC2=CNC3=CC=C(C=C32)Cl)=NO1 SYGNEIOTGIUEDM-UHFFFAOYSA-N 0.000 description 1
- NWXZVXWTRKCMJB-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(2,5-difluorobenzoyl)-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=C(F)C(C(=O)C=2ON=C(C=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1 NWXZVXWTRKCMJB-UHFFFAOYSA-N 0.000 description 1
- QMJKGJSBFVHBKS-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(2,5-difluorophenyl)-1,2,4-oxadiazole-3-carboxamide Chemical compound FC1=CC=C(F)C(C=2ON=C(N=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1 QMJKGJSBFVHBKS-UHFFFAOYSA-N 0.000 description 1
- LBXNTBRPTUZPCD-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(4-chlorophenyl)-1,2-oxazole-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 LBXNTBRPTUZPCD-UHFFFAOYSA-N 0.000 description 1
- VFFAOEROEARGPP-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(4-chlorophenyl)-2-methylfuran-3-carboxamide Chemical compound C=1C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C(C)OC=1C1=CC=C(Cl)C=C1 VFFAOEROEARGPP-UHFFFAOYSA-N 0.000 description 1
- ZVRKDYCQPDVLPJ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(4-methoxyphenyl)-1,2-oxazole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1C1=CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 ZVRKDYCQPDVLPJ-UHFFFAOYSA-N 0.000 description 1
- JJUXJQWEYOIFCX-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(4-methylphenyl)-1,2-oxazole-3-carboxamide Chemical compound C1=CC(C)=CC=C1C1=CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 JJUXJQWEYOIFCX-UHFFFAOYSA-N 0.000 description 1
- RZQZAFCHIISCDC-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(diethylaminomethyl)-1,2-oxazole-3-carboxamide Chemical compound O1C(CN(CC)CC)=CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=N1 RZQZAFCHIISCDC-UHFFFAOYSA-N 0.000 description 1
- RFFSMTMCJLPAPN-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(dimethylamino)-1,2-oxazole-3-carboxamide Chemical compound O1C(N(C)C)=CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=N1 RFFSMTMCJLPAPN-UHFFFAOYSA-N 0.000 description 1
- OOEHBOUHQRBFEY-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(ethoxymethyl)-1,2-oxazole-3-carboxamide Chemical compound O1C(COCC)=CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=N1 OOEHBOUHQRBFEY-UHFFFAOYSA-N 0.000 description 1
- WOEXIGNIOLJXDF-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(ethoxymethyl)-4,5-dihydro-1,2-oxazole-3-carboxamide Chemical compound O1C(COCC)CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=N1 WOEXIGNIOLJXDF-UHFFFAOYSA-N 0.000 description 1
- NQNMWXOFSGKOOV-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(ethylaminomethyl)-1,2-oxazole-3-carboxamide Chemical compound O1C(CNCC)=CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=N1 NQNMWXOFSGKOOV-UHFFFAOYSA-N 0.000 description 1
- YEFXTMMDQABUTN-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(furan-2-yl)-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(=NO1)C=C1C1=CC=CO1 YEFXTMMDQABUTN-UHFFFAOYSA-N 0.000 description 1
- GUDXTJRZACKPJB-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(furan-2-yl)-1-methylpyrazole-3-carboxamide Chemical compound CN1N=C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)C=C1C1=CC=CO1 GUDXTJRZACKPJB-UHFFFAOYSA-N 0.000 description 1
- YUQVJBGIIWDKGU-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(furan-2-ylmethyl)-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(=NO1)C=C1CC1=CC=CO1 YUQVJBGIIWDKGU-UHFFFAOYSA-N 0.000 description 1
- MFIFMLCVMNABDB-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(furan-3-ylmethyl)-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(=NO1)C=C1CC=1C=COC=1 MFIFMLCVMNABDB-UHFFFAOYSA-N 0.000 description 1
- XULLDWHFHIFMCL-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(hydroxymethyl)-1,2-oxazole-3-carboxamide Chemical compound O1C(CO)=CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=N1 XULLDWHFHIFMCL-UHFFFAOYSA-N 0.000 description 1
- BRSJPTCRDCOEMN-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(pyrazol-1-ylmethyl)-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(=NO1)C=C1CN1C=CC=N1 BRSJPTCRDCOEMN-UHFFFAOYSA-N 0.000 description 1
- PGFYSSVZTMSVQW-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(pyridin-4-ylmethyl)-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(=NO1)C=C1CC1=CC=NC=C1 PGFYSSVZTMSVQW-UHFFFAOYSA-N 0.000 description 1
- HQZVBFBFHCECIO-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(pyrrolidin-1-ylmethyl)-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(=NO1)C=C1CN1CCCC1 HQZVBFBFHCECIO-UHFFFAOYSA-N 0.000 description 1
- LJKPWHFAPQHXOZ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(thiophen-2-ylmethyl)-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(=NO1)C=C1CC1=CC=CS1 LJKPWHFAPQHXOZ-UHFFFAOYSA-N 0.000 description 1
- ITRNRGMMTHHLRS-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(thiophen-3-ylmethyl)-1,2,4-oxadiazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(N=1)=NOC=1CC=1C=CSC=1 ITRNRGMMTHHLRS-UHFFFAOYSA-N 0.000 description 1
- DVZXJWUDLZHYFX-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-(thiophen-3-ylmethyl)-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(=NO1)C=C1CC=1C=CSC=1 DVZXJWUDLZHYFX-UHFFFAOYSA-N 0.000 description 1
- GELYHRNUGQEFSM-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(2,3-difluorophenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound FC1=CC=CC(CC=2ON=C(N=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1F GELYHRNUGQEFSM-UHFFFAOYSA-N 0.000 description 1
- FXVIGYSZMYFKMU-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(2,3-difluorophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=CC(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1F FXVIGYSZMYFKMU-UHFFFAOYSA-N 0.000 description 1
- RTSFAGMKULEEFP-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(2,4,6-trifluorophenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound FC1=CC(F)=CC(F)=C1CC1=NC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 RTSFAGMKULEEFP-UHFFFAOYSA-N 0.000 description 1
- LJVPDVMMYKLLDS-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(2,4-difluorophenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound FC1=CC(F)=CC=C1CC1=NC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 LJVPDVMMYKLLDS-UHFFFAOYSA-N 0.000 description 1
- YTIKRIIOAQZCHT-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(2,5-difluorophenyl)-difluoromethyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=C(F)C(C(F)(F)C=2ON=C(C=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1 YTIKRIIOAQZCHT-UHFFFAOYSA-N 0.000 description 1
- AIONHBUCVONOCZ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(2,5-difluorophenyl)-fluoromethyl]-1,2-oxazole-3-carboxamide Chemical compound C=1C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NOC=1C(F)C1=CC(F)=CC=C1F AIONHBUCVONOCZ-UHFFFAOYSA-N 0.000 description 1
- RJCJIODUUNECAY-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(2,5-difluorophenyl)-hydroxymethyl]-1,2-oxazole-3-carboxamide Chemical compound C=1C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NOC=1C(O)C1=CC(F)=CC=C1F RJCJIODUUNECAY-UHFFFAOYSA-N 0.000 description 1
- JLKFYZOVYQASFU-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(2,5-difluorophenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound FC1=CC=C(F)C(CC=2ON=C(N=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1 JLKFYZOVYQASFU-UHFFFAOYSA-N 0.000 description 1
- XNZLYFGWYOCRDG-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(2,5-difluorophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=C(F)C(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1 XNZLYFGWYOCRDG-UHFFFAOYSA-N 0.000 description 1
- OMJRWDYQUQAMLH-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(2,6-difluorophenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound FC1=CC=CC(F)=C1CC1=NC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 OMJRWDYQUQAMLH-UHFFFAOYSA-N 0.000 description 1
- YENBMKSEAIPDEC-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(2-chlorophenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(N=1)=NOC=1CC1=CC=CC=C1Cl YENBMKSEAIPDEC-UHFFFAOYSA-N 0.000 description 1
- BZRWXHKYOTXAQN-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(2-fluoro-3-methoxyphenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound COC1=CC=CC(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1F BZRWXHKYOTXAQN-UHFFFAOYSA-N 0.000 description 1
- XTNQMIDXUZIYAP-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(2-fluorophenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound FC1=CC=CC=C1CC1=NC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 XTNQMIDXUZIYAP-UHFFFAOYSA-N 0.000 description 1
- WIYWIEYKFCZDEC-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(2-methoxyphenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound COC1=CC=CC=C1CC1=NC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 WIYWIEYKFCZDEC-UHFFFAOYSA-N 0.000 description 1
- GCAASTJNRFWUTO-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(2-methoxyphenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound COC1=CC=CC=C1CC1=CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 GCAASTJNRFWUTO-UHFFFAOYSA-N 0.000 description 1
- HLHPXPWSHAUJMQ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(2-methylphenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound CC1=CC=CC=C1CC1=NC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 HLHPXPWSHAUJMQ-UHFFFAOYSA-N 0.000 description 1
- DKWVELYOGVGGDZ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(3,4-dichlorophenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(N=1)=NOC=1CC1=CC=C(Cl)C(Cl)=C1 DKWVELYOGVGGDZ-UHFFFAOYSA-N 0.000 description 1
- LXURCKIPYOITED-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(3,4-difluorophenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CC1=NC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 LXURCKIPYOITED-UHFFFAOYSA-N 0.000 description 1
- QBGDNGHFRWTIDB-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(3,4-difluorophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CC1=CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 QBGDNGHFRWTIDB-UHFFFAOYSA-N 0.000 description 1
- QWTZLJIBSFBBJO-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(3,4-dimethoxyphenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 QWTZLJIBSFBBJO-UHFFFAOYSA-N 0.000 description 1
- RYPGQLLKFHITTN-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(3,5-difluorophenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound FC1=CC(F)=CC(CC=2ON=C(N=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1 RYPGQLLKFHITTN-UHFFFAOYSA-N 0.000 description 1
- XMGQCYFHJLNIBX-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(3,5-difluorophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC(F)=CC(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1 XMGQCYFHJLNIBX-UHFFFAOYSA-N 0.000 description 1
- CVASLDATZCMQNJ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(3-chlorophenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound ClC1=CC=CC(CC=2ON=C(N=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1 CVASLDATZCMQNJ-UHFFFAOYSA-N 0.000 description 1
- XSKNQCSFUCARIA-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(3-cyanophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(=NO1)C=C1CC1=CC=CC(C#N)=C1 XSKNQCSFUCARIA-UHFFFAOYSA-N 0.000 description 1
- MHWZUSMKYYFLRQ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(3-fluorophenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound FC1=CC=CC(CC=2ON=C(N=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1 MHWZUSMKYYFLRQ-UHFFFAOYSA-N 0.000 description 1
- NCHQAYTVFNWHAX-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(3-fluorophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=CC(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1 NCHQAYTVFNWHAX-UHFFFAOYSA-N 0.000 description 1
- UFCDEAZMMATSOA-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(3-methoxyphenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound COC1=CC=CC(CC=2ON=C(N=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1 UFCDEAZMMATSOA-UHFFFAOYSA-N 0.000 description 1
- ISAWHMUBLQJDBR-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(3-methoxyphenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound COC1=CC=CC(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1 ISAWHMUBLQJDBR-UHFFFAOYSA-N 0.000 description 1
- PGRQQCYCOQVRIZ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(3-methylphenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound CC1=CC=CC(CC=2ON=C(N=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1 PGRQQCYCOQVRIZ-UHFFFAOYSA-N 0.000 description 1
- HRGOUXKXSMRGPZ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(3-methylphenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound CC1=CC=CC(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1 HRGOUXKXSMRGPZ-UHFFFAOYSA-N 0.000 description 1
- HCLVKOVSKMZWBG-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(4-chlorophenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1CC1=NC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 HCLVKOVSKMZWBG-UHFFFAOYSA-N 0.000 description 1
- SZWGEWYQIZIADW-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(4-cyanophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(=NO1)C=C1CC1=CC=C(C#N)C=C1 SZWGEWYQIZIADW-UHFFFAOYSA-N 0.000 description 1
- OCMYWCHYLUOVAP-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(4-fluorophenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound C1=CC(F)=CC=C1CC1=NC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 OCMYWCHYLUOVAP-UHFFFAOYSA-N 0.000 description 1
- JXMGVHIKLZSPTK-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(4-methoxyphenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1CC1=NC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 JXMGVHIKLZSPTK-UHFFFAOYSA-N 0.000 description 1
- AXBCDOSSFVUYNX-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(4-methoxyphenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound C1=CC(OC)=CC=C1CC1=CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 AXBCDOSSFVUYNX-UHFFFAOYSA-N 0.000 description 1
- LOOUKVPKYDRYMG-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(4-methylphenyl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound C1=CC(C)=CC=C1CC1=NC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 LOOUKVPKYDRYMG-UHFFFAOYSA-N 0.000 description 1
- JHGTZCRLDXXCMH-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(4-methylphenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound C1=CC(C)=CC=C1CC1=CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 JHGTZCRLDXXCMH-UHFFFAOYSA-N 0.000 description 1
- QWIQFUBVIANPHI-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound N=1C(CC=2ON=C(N=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C(C)OC=1C1=CC=CC=C1 QWIQFUBVIANPHI-UHFFFAOYSA-N 0.000 description 1
- KFYGYDUEDZCAHW-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]-1,2,4-oxadiazole-3-carboxamide Chemical compound FC1=CC=C(C(F)(F)F)C=C1CC1=NC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 KFYGYDUEDZCAHW-UHFFFAOYSA-N 0.000 description 1
- HPSZOFHKRBIHKJ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[[3-(trifluoromethyl)phenyl]methyl]-1,2-oxazole-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1 HPSZOFHKRBIHKJ-UHFFFAOYSA-N 0.000 description 1
- VEYNJCKPNGBZFE-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[[4-(trifluoromethyl)phenyl]methyl]-1,2-oxazole-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CC1=CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NO1 VEYNJCKPNGBZFE-UHFFFAOYSA-N 0.000 description 1
- BFYXMARVBGSUFE-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-[hydroxy(phenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound C=1C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=NOC=1C(O)C1=CC=CC=C1 BFYXMARVBGSUFE-UHFFFAOYSA-N 0.000 description 1
- HYROIWOOJLSYMY-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-cyclohexyl-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(=NO1)C=C1C1CCCCC1 HYROIWOOJLSYMY-UHFFFAOYSA-N 0.000 description 1
- ZRWFURWRALQTKJ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-cyclohexyl-1,3,4-oxadiazole-2-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(O1)=NN=C1C1CCCCC1 ZRWFURWRALQTKJ-UHFFFAOYSA-N 0.000 description 1
- GGBJBFGKQXZJFD-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-cyclohexyl-4,5-dihydro-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(C1)=NOC1C1CCCCC1 GGBJBFGKQXZJFD-UHFFFAOYSA-N 0.000 description 1
- NVWZFJTYFUVDDY-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-cyclopropyl-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(=NO1)C=C1C1CC1 NVWZFJTYFUVDDY-UHFFFAOYSA-N 0.000 description 1
- LTMMNOLXWXCXFP-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound O1C(C)=CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=N1 LTMMNOLXWXCXFP-UHFFFAOYSA-N 0.000 description 1
- SISAUIJXSFYIOJ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-methyl-2-phenyl-1,3-oxazole-4-carboxamide Chemical compound N=1C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C(C)OC=1C1=CC=CC=C1 SISAUIJXSFYIOJ-UHFFFAOYSA-N 0.000 description 1
- LZRFWFKUGKIKMS-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-methyl-2-phenylfuran-3-carboxamide Chemical compound O1C(C)=CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=C1C1=CC=CC=C1 LZRFWFKUGKIKMS-UHFFFAOYSA-N 0.000 description 1
- PBMMCVIINMEGGY-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-methyl-2-phenyltriazole-4-carboxamide Chemical compound N1=C(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)C(C)=NN1C1=CC=CC=C1 PBMMCVIINMEGGY-UHFFFAOYSA-N 0.000 description 1
- BNULMSOUSBZSFZ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-methyl-3-phenyl-1,2-oxazole-4-carboxamide Chemical compound C=1NC2=CC=C(Cl)C=C2C=1CCNC(=O)C1=C(C)ON=C1C1=CC=CC=C1 BNULMSOUSBZSFZ-UHFFFAOYSA-N 0.000 description 1
- JZDYZHBKYOIQPI-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-oxo-1-phenylpyrrolidine-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(CC1=O)CN1C1=CC=CC=C1 JZDYZHBKYOIQPI-UHFFFAOYSA-N 0.000 description 1
- WGWAOKRPBSARSA-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-phenyl-1,2,4-oxadiazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(N=1)=NOC=1C1=CC=CC=C1 WGWAOKRPBSARSA-UHFFFAOYSA-N 0.000 description 1
- OUASKMLAWUELHZ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-phenyl-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(=NO1)C=C1C1=CC=CC=C1 OUASKMLAWUELHZ-UHFFFAOYSA-N 0.000 description 1
- TZBVJOVSRYRFLV-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-phenyl-1,3,4-oxadiazole-2-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(O1)=NN=C1C1=CC=CC=C1 TZBVJOVSRYRFLV-UHFFFAOYSA-N 0.000 description 1
- GTMMFQCWOILPCP-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-phenyl-1,3-oxazole-2-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(O1)=NC=C1C1=CC=CC=C1 GTMMFQCWOILPCP-UHFFFAOYSA-N 0.000 description 1
- CXNYJAMIQUSBJF-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-phenyl-1,3-oxazole-4-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C=1N=COC=1C1=CC=CC=C1 CXNYJAMIQUSBJF-UHFFFAOYSA-N 0.000 description 1
- IFMVBMAGCRRTJY-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-phenyl-4,5-dihydro-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(C1)=NOC1C1=CC=CC=C1 IFMVBMAGCRRTJY-UHFFFAOYSA-N 0.000 description 1
- WKLBGDFDYWFJTJ-UHFFFAOYSA-N n-[2-(5-chloro-1h-indol-3-yl)ethyl]-5-thiophen-2-yl-1,2-oxazole-3-carboxamide Chemical compound C12=CC(Cl)=CC=C2NC=C1CCNC(=O)C(=NO1)C=C1C1=CC=CS1 WKLBGDFDYWFJTJ-UHFFFAOYSA-N 0.000 description 1
- KUNGNGUYZSWYAC-UHFFFAOYSA-N n-[2-(5-chloro-1h-pyrrolo[2,3-b]pyridin-3-yl)ethyl]-5-(2,5-difluorobenzoyl)-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=C(F)C(C(=O)C=2ON=C(C=2)C(=O)NCCC=2C3=CC(Cl)=CN=C3NC=2)=C1 KUNGNGUYZSWYAC-UHFFFAOYSA-N 0.000 description 1
- OXVOVTFKGKWPNE-UHFFFAOYSA-N n-[2-(5-chloro-1h-pyrrolo[2,3-b]pyridin-3-yl)ethyl]-5-[(2,5-difluorophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=C(F)C(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC(Cl)=CN=C3NC=2)=C1 OXVOVTFKGKWPNE-UHFFFAOYSA-N 0.000 description 1
- ZRJFCYLYUWLVHH-UHFFFAOYSA-N n-[2-(5-chloro-2-methyl-1h-indol-3-yl)ethyl]-5-[(2,5-difluorophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound CC=1NC2=CC=C(Cl)C=C2C=1CCNC(=O)C(=NO1)C=C1CC1=CC(F)=CC=C1F ZRJFCYLYUWLVHH-UHFFFAOYSA-N 0.000 description 1
- FPJXGEBTXWTCGZ-UHFFFAOYSA-N n-[2-(5-chloro-7-fluoro-1h-indol-3-yl)ethyl]-5-[(2,5-difluorophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=C(F)C(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC(Cl)=CC(F)=C3NC=2)=C1 FPJXGEBTXWTCGZ-UHFFFAOYSA-N 0.000 description 1
- XLEPECJBPLBORI-UHFFFAOYSA-N n-[2-(5-cyano-1h-indol-3-yl)ethyl]-5-[(2,5-difluorophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=C(F)C(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC(=CC=C3NC=2)C#N)=C1 XLEPECJBPLBORI-UHFFFAOYSA-N 0.000 description 1
- RIINZTXUNOTFQR-UHFFFAOYSA-N n-[2-(5-fluoro-1h-indol-3-yl)ethyl]-4-methyl-2-(4-methylphenyl)-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NCCC=2C3=CC(F)=CC=C3NC=2)=C(C)N=C1C1=CC=C(C)C=C1 RIINZTXUNOTFQR-UHFFFAOYSA-N 0.000 description 1
- NBCKDDODXUUTPX-UHFFFAOYSA-N n-[2-(5-fluoro-1h-indol-3-yl)ethyl]-5-[(3-fluorophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=CC(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC(F)=CC=C3NC=2)=C1 NBCKDDODXUUTPX-UHFFFAOYSA-N 0.000 description 1
- VWGOZNSCHCEFOW-UHFFFAOYSA-N n-[2-(5-methoxy-1h-indol-3-yl)ethyl]-4-methyl-2-(4-methylphenyl)-1,3-thiazole-5-carboxamide Chemical compound C12=CC(OC)=CC=C2NC=C1CCNC(=O)C(=C(N=1)C)SC=1C1=CC=C(C)C=C1 VWGOZNSCHCEFOW-UHFFFAOYSA-N 0.000 description 1
- NNYDHTCUFBGUOO-UHFFFAOYSA-N n-[2-(5-methoxy-1h-indol-3-yl)ethyl]-5-methyl-3-phenyl-1,2-oxazole-4-carboxamide Chemical compound C12=CC(OC)=CC=C2NC=C1CCNC(=O)C1=C(C)ON=C1C1=CC=CC=C1 NNYDHTCUFBGUOO-UHFFFAOYSA-N 0.000 description 1
- GCYKGNRMWWPSMX-UHFFFAOYSA-N n-[2-(6-chloro-5-methyl-1h-indol-3-yl)ethyl]-5-[(2,5-difluorophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound C=1NC=2C=C(Cl)C(C)=CC=2C=1CCNC(=O)C(=NO1)C=C1CC1=CC(F)=CC=C1F GCYKGNRMWWPSMX-UHFFFAOYSA-N 0.000 description 1
- UOZITCDJSMICGM-UHFFFAOYSA-N n-[2-(6-fluoro-1h-indol-3-yl)ethyl]-5-[(3-fluorophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=CC(CC=2ON=C(C=2)C(=O)NCCC=2C3=CC=C(F)C=C3NC=2)=C1 UOZITCDJSMICGM-UHFFFAOYSA-N 0.000 description 1
- PRLPOGGTMIVPKN-UHFFFAOYSA-N n-[3-(5-chloro-1h-indol-3-yl)propyl]-5-[(3-fluorophenyl)methyl]-1,2-oxazole-3-carboxamide Chemical compound FC1=CC=CC(CC=2ON=C(C=2)C(=O)NCCCC=2C3=CC(Cl)=CC=C3NC=2)=C1 PRLPOGGTMIVPKN-UHFFFAOYSA-N 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007996 neuronal plasticity Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000004944 pyrazin-3-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical group C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 description 1
- 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical compound [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 1
- 229910000080 stannane Inorganic materials 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- LUIPMZWXADUQBM-UHFFFAOYSA-N tert-butyl n-[3-[2-(5-chloro-1h-indol-3-yl)ethylcarbamoyl]-1,2-oxazol-5-yl]carbamate Chemical compound O1C(NC(=O)OC(C)(C)C)=CC(C(=O)NCCC=2C3=CC(Cl)=CC=C3NC=2)=N1 LUIPMZWXADUQBM-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000005032 thiofuranyl group Chemical group S1C(=CC=C1)* 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to novel compounds and to the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic ⁇ -synuclein amyloidogenesis.
- the present invention also relates to the compounds for use as a medicaments and to the use of said compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders.
- the present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.
- TAU is an intracellular protein with the ability to bind and consequently stabilise and define microtubule structure and function. Apart from this physiological function TAU also plays a direct role in numerous neurodegenerative disorders collectively known as "tauopathies" with the most notable examples being Alzheimer's disease, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).
- tauopathies neurodegenerative disorders
- FTDP-17 parkinsonism linked to chromosome 17
- Tauopathies are characterised by insoluble aggregates or polymers of tau which are formed by self-polymerisation of tau monomers.
- the precise molecular mechanisms involved in TAU aggregation is not clearly known but may involve partial denaturation or misfolding of the TAU protein in conformations with a high propensity to self-organise into higher order structures.
- An important aspect of the TAU aggregation is its inherent cytotoxicity, which reduces cellular integrity or even triggers cell death. In case of neurodegenerative diseases, loss of affected neurons leads to cognitive and/or motor dysfunctioning.
- a direct role of TAU in disease onset has been established unequivocally by the elucidation of familial mutations in TAU which appear to be responsible for a very early and sometimes aggressive form of tauopathy. Such mutations comprise changes in the amino acid sequence of TAU that promote toxic aggregation and thereby provoke loss of cellular integrity.
- ⁇ -Synuclein is a neuronal protein which originally has been associated with neuronal plasticity during Zebra finch song learning.
- human ⁇ -synuclein Apart from its physiological role in brain cells, human ⁇ -synuclein also possesses pathological features that underlies a plethora of neurodegenerative diseases including Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, multiple system atrophy and Alzheimer's disease.
- These neurological disorders are characterised by the presence of insoluble ⁇ -synuclein polymers or aggregates usually residing within neuronal cells, although in the case of Alzheimer's disease ⁇ - synuclein (or proteolytic fragments thereof) constitutes the non-amyloid component of extracellular " amyloid- ⁇ plaques ". It is widely believed that the amyloidogenic properties ⁇ -synuclein disrupt cellular integrity leading to dysfunctioning or death of affected neurons resulting in cognitive and/or motoric decline as it is found in patients suffering from such diseases.
- ROS reactive oxygen species
- paraquat an agent stimulating ROS formation within the cell
- ROS reactive oxygen species
- ⁇ -synuclein aggregation a stimulator of ⁇ -synuclein aggregation.
- exposure to paraquat is believed to induce the formation of synuclein inclusions, and consequently neurodegeneration, especially of dopaminergic neurons in humans.
- Dopaminergic neurons appear to be particularly sensitive because the concurrent dopamine metabolism may on the one hand contribute significantly to the oxidative stress load but may on the other hand result in kinetic stabilisation of highly toxic protofibrillar ⁇ - synuclein species by dopamine (or its metabolic derivatives).
- Parkinson's disease is characterised by a selective loss of dopaminergic substantia nigra cells and therefore treatment of animals (or neuronal cells) with paraquat is a common well-accepted experimental set-up for studying synucleopathies, in particular Parkinson's disease.
- insoluble aggregates affect cellular integrity
- soluble protofibrillar intermediates of the aggregation process are particularly toxic for the cell as opposed to mature insoluble fibrils which may be inert end-products or may even serve as cytoprotective reservoirs of otherwise harmful soluble species.
- Therapeutic attempts to inhibit formation of insoluble aggregates may therefore be conceptually wrong, possibly even promoting disease progress.
- the present invention is based on the unexpected finding that at least one of the above-mentioned problems can be solved by a novel class of compounds.
- the present invention provides compounds which are useful for preventing or treating neurodegenerative disorders, especially tauopathies.
- the present invention demonstrates that these compounds efficiently inhibit the tau-aggregation induced toxicity which is responsible for neurodegeneration. Therefore, these novel compounds constitute a useful class of compounds that can be used in the treatment and/or prevention of neurodegenerative disorders in animals, more specifically in humans.
- a first aspect of the present invention therefore provides compounds according to formula (AA1 ),
- each dotted line individually represents an optional double bond, wherein maximally two dotted lines selected from the five dotted lines are a double bond;
- E 1 is independently selected from CR 1 ; and N;
- E 2 is independently selected from NR 2 ; and O;
- E 3 is independently selected from CR 3 ; and N;
- R a is hydrogen or can be taken together with R b to form a substituted or unsubstituted
- R b is hydrogen or can be taken together with R a to form a substituted or unsubstituted
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally includes one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatoms being selected from the atoms O, S and N;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene can be unsubstituted or substituted with Z;
- - R 2 is selected from hydrogen; alkyl; alkenyl; and alkynyl; n is selected from O; 1 or 2; - each of X, Y, T, W and V is independently selected from -CZ 1 H-; -CZ 1 -; -C-; -N-;
- NR 101 -0-; -S-; or -CO-; wherein at least one of X, Y, T; W or V is selected from
- Y is selected from -CZ 1 -; -C-; or -N-; - L is independently selected from being not present; -O-; -NH-; -NR 10 -; Ci -6 alkylene;
- Ci_ 6 alkenylene Ci -6 alkynylene
- each of said Ci -6 alkylene, Ci -6 alkenylene or Ci -6 alkynylene optionally includes one or more heteroatoms, said heteroatoms being selected from the heteroatoms consisting of O, S and N, and wherein each of said Ci -6 alkylene, Ci- ⁇ slkenylene or can be unsubstituted or substituted;
- Ci -6 alkylene Ci -6 alkenylene or Ci -6 alkynylene
- B represents a cyclic structure selected from cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; and heterocycle; - m is selected from O; 1 ; 2; 3; 4 and 5;
- R 8 is independently selected from hydrogen; halogen; alkyl; alkenyl; alkynyl; -OH; - OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; - NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ; * wherein said alkyl, alkenyl and alkynyl optionally includes one or more heteroatoms, said heteroatoms being selected from the
- each Z is independently selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; - S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; - NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; - NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- each R 101 is independently selected from hydrogen and R 10 ; each R 11 is independently selected from hydroxyl; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene or heterocycle-alkynylene;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- each R 12 and R 13 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene or heterocycle-alkynylene;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- R 12 and R 13 can be taken together in order to form a (5-, 6-, or 7- membered) heterocycle which can be unsubstituted or substituted; and isomers (in particular stereoisomers, enantiomers or tautomers), solvates, hydrates, salts (in particular pharmaceutically acceptable salts) or prodrugs thereof.
- L is selected from -0-; -
- L is selected from -0-; -NH-; -NR 10 -; Ci -3 alkylene; Ci -3 alkenylene; Ci -3 alkynylene; yet more in particular L is selected from -0-; -NH-; -NR 10 -; Ci -2 alkylene; Ci -2 alkenylene; C 1-2 alkynylene; still more in particular L is selected from -0-; -NH-; -NR 10 -; and -CH 2 - ; yet still more in particular L is -
- the compounds of the invention are not selected from N-[2-(5-chloro-2-methyl-1 H-indol-3-yl)ethyl]-1 -(tetrahydro-2-furanylmethyl)-1 H-1 ,2,3- triazole-4-carboxamide.
- R 5 is halogen.
- R 5 can not be Cl, while R 2 is Me.
- each of X, Y, T, W and V is independently selected from -CZ 1 H-; -CZ 1 -; -C-; -N-; NR 101 ; - 0-; -S-; or -CO-; and form with the dotted lines one of the cycles having one of the structural formula (Ia), (Na), (IVa), (Va), (Via), (Vila), (Villa), (IXa), (Xa), (XIa), (XIIa), (XIIIa), (XIVa), (XVa), (XVIa), (XVIIa), (XVIIIa), (XIXa), (XXa), (XXIa), (XXIIa), (XXIIIa) or (XXIVa):
- the present invention concerns compound of formula (AA1 ), or a stereoisomer, enantiomer or tautomer thereof wherein each dotted line individually represents an optional double bond, wherein maximally two dotted lines selected from the five dotted lines are a double bond; E 1 is independently selected from CR 1 ; and N; E 2 is independently selected from NR 2 ; and O; E 3 is independently selected from CR 3 ; and N; - Q is independently selected from NR b -C(O); C(O); and C(O)NH; R a is hydrogen or can be taken together with R b to form a substituted or unsubstituted unsaturated 4, 5, 6, 7 or 8 membered ring containing one N atom; R b is hydrogen or can be taken together with R a to form a substituted or unsubstituted unsaturated 4, 5, 6, 7 or 8 membered ring containing one N atom; - each R 1 , R 3 , R 4 , and R 6 is
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally includes one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatoms being selected from the atoms O, S and N;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene can be unsubstituted or substituted with Z;
- R 2 is selected from hydrogen; alkyl; alkenyl; and alkynyl; - R 5 is selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; - SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -
- n is selected from O; 1 or 2;
- B represents a cyclic structure selected from cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; and heterocycle; m is selected from 0; 1 ; 2; 3; 4 and 5;
- R 8 is independently selected from hydrogen; halogen; alkyl; alkenyl; alkynyl; -OH; -
- OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; - NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ;
- alkyl, alkenyl and alkynyl optionally includes one or more heteroatoms, said heteroatoms being selected from the atoms O, S and N;
- each Z is independently selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; - S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; - NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; - NR 12 ;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- each R 12 and R 13 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene or heterocycle-alkynylene;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- R 12 and R 13 can be taken together in order to form a (5-, 6-, or 7- membered) heterocycle which can be unsubstituted or substituted;
- L is independently selected from -0-; -NH-; -NR 10 -; Ci -6 alkylene; Ci- 6 alkenylene; Ci -6 alkynylene; * wherein each of said optionally includes one or more heteroatoms, said heteroatoms being selected from the heteroatoms consisting of S and N, and wherein each of said d ⁇ alkylene, Ci- 6 alkenylene or Ci -6 alkynylene, can be unsubstituted or substituted;
- L is a straight unbranched linking chain of atoms linking B with the five membered ring, whereby said straight linking chain of atoms is maximally three, more specifically two, yet more specifically one atom long, whereby said atoms are selected from C, O and N.
- L is selected from -O-; -
- L is selected from -O-; -NH-; -NR 10 -; Ci -3 alkylene; Ci -3 alkynylene; yet more in particular L is selected from -O-; -NH-; -NR 10 -; Ci -2 alkylene; Ci -2 alkenylene; Ci -2 alkynylene; still more in particular L is selected from -O-; -NH-; -NR 10 -; and -CH 2 - ; yet still more in particular L is - CH 2 -.
- the compounds of the invention are not selected from N-[2-(5-chloro-2-methyl-1 H-indol-3-yl)ethyl]-1 -(tetrahydro-2-furanylmethyl)-1 H-1 ,2,3- triazole-4-carboxamide.
- L is a single bond or is not present for a selection of compounds whereby X, Y, T, W and V form with the dotted lines formulae described herein, such as for formula (III).
- R 5 is halogen. In yet another particular embodiment, R 5 can not be Cl, while R 1 is Me.
- each of X, Y, T, W and V form with the dotted lines formula (Vl)
- the Z 1 substituent in such formula (Vl) is selected from hydrogen.
- each of X, Y, T, W and V can not form with the dotted lines formula (Vl).
- each of X, Y, T, W and V can not form with the dotted lines formula (IV), (XVI), or (XX).
- each of X, Y, T, W and V is independently selected from -CZ 1 H-; -CZ 1 -; -C-; -N-; NR 101 ; -O-; -S-; or -CO-; and form with the dotted lines one of the cycles having one of the structural formula (Ia), (Na), (Ilia), (Va), (Vila), (Villa), (IXa), (Xa), (XIa), (XIIa), (XIIIa), (XIVa), (XVa), (XVIa), (XVIIa), (XVIIIa), (XIXa), (XXa), (XXIa), (XXIIa), (XXIIIa) or (XXIVa), more in particular having one of the structural formula (Ia), (Na), (Va), (XVIIIa), (XXIIa), (XXIIIa) or (XXIVa), more in particular having one of the structural formula
- each R 1 , R 3 , R 4 , and R 6 is independently selected from hydrogen; halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; - NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; - C(O)NR 12 R 13 ; -C(O)R 11 ; alkyl; alkenyl; and alkynyl.
- each R 1 , R 3 , R 4 , and R 6 is independently selected from hydrogen; halogen; -OH; -OR 10 ; -SH; -SR 10 ; trifluoromethyl; trifluoromethoxy; nitro; alkyl; alkenyl; and alkynyl.
- R 1 is hydrogen or alkyl, more in particular is hydrogen.
- R 2 is hydrogen or alkyl, yet more in particular is hydrogen.
- R 3 is hydrogen.
- R 4 is hydrogen.
- R 6 is hydrogen.
- R 3 , R 4 and R 6 are hydrogen.
- R 1 and R 2 are each hydrogen when X, Y, T, W and V form the cycle of formulae (Vl), (XVI) or (XX).
- R 8 is not selected from -NHC(O)R 10 .
- R 8 is not 2-methylenetetrahydrofuranyl.
- R 8 is selected from hydrogen; halogen; alkyl; alkenyl; alkynyl; -OH; -OR 10 ; - SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; - NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; - NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ; wherein
- R 8 is selected from hydrogen; halogen; alkyl; alkenyl; alkynyl; -OH; -OR 10 ; -SH; -SR 10 ; trifluoromethyl; trifluoromethoxy; -NR 12 R 13 ; - cyano.
- R 8 is selected from hydrogen; halogen; linear alkyl; linear alkenyl; linear alkynyl; -OH; -OR 10 ; -SH; -SR 10 ; trifluoromethyl; trifluoromethoxy; -NR 12 R 13 ; -cyano.
- R 8 does not comprise a cyclic ring structure (for example selected from cyclic alkyl, cyclic alkenyl, cyclic alkynyl, aryl or heterocycle).
- R 8 is halogen, yet more in particular is fluor.
- R 8 is not 2-methylenetetrahydrofuranyl and R 2 is hydrogen when X, Y, T, W and V form the cycle of formula (Vl).
- m is 2.
- the compounds of the invention comprise maximally three monocyclic or cyclic fused ring systems selected from aryl or heterocycle. In yet another particular embodiment, the compounds of the invention comprise maximally ring systems, whereby said three ring systems consist of: - indole;
- each of X, Y, T, W and V is independently selected from -CZ 1 H-; -CZ 1 -; -C-; -N-; NR 101 ; -O-; -S-; or -CO-; and are more in particular selected from (Ia), (Na), (IVa), (Va), (Via), (Vila), (Villa), (IXa), (Xa), (XIa), (XIIa), (XIIIa),
- - Z 1 is independently selected from hydrogen, alkyl and Z; - Z is independently selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; - SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; - NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; - COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ;
- each of X, Y, T, W and V is independently selected from -CZ 1 H-; -CZ 1 -; -C-; -N-; NR 101 ; -0-; -S-; or -CO-; and are more in particular selected from (Ia), (Na), (IVa), (Va), (Via), (Vila), (Villa), (IXa), (Xa), (XIa), (XIIa), (XIIIa), (XIVa), (XVa), (XVIa), (XVIIa), (XVIIIa), (XIXa), (XXa), (XXIa), (XXIIa), (XXIIIa) or (XXIVa): wherein - Z 1 is independently selected from hydrogen; alkyl; halogen; -OH; -OR 10 ; -SH; -SR 10 ; -
- each of X, Y, T, W and V is independently selected from -CH 2 -; -CH-; -C-; -N-; NH; -0-; -S-; or -CO-.
- each of X, Y, T, W and V is independently selected from -CH 2 -; -CH-; -C-; -N-; NH; -0-; -S-; or -CO- and form with the dotted lines one of the cycles having one of the structural formula (Ia'), (Na'), (NIa'), (Va'), (Vila'), (VIIIa'), (Ixa'), (Xa'), (Xia'), (XIIa'), (XIIIa'), (XIVa'), (Xva'), (XVIa'), (XVIIa'), (XVIIIa'), (XIXa'), (Xxa'), (XXIa'), (XXIIa'), (XXIIIa') or (XXIVa'):
- the present invention concerns compound of formula (AA1 ), or a stereoisomer, enantiomer or tautomer thereof wherein - each dotted line individually represents an optional double bond, wherein maximally two dotted lines selected from the five dotted lines are a double bond; E 1 is independently selected from CR 1 ; and N; E 2 is independently selected from NR 2 ; and O; E 3 is independently selected from CR 3 ; and N; - Q is independently selected from NR b -C(O); C(O); and C(O)NH; R a is hydrogen or can be taken together with R b to form a substituted or unsubstituted unsaturated 4, 5, 6, 7 or 8 membered ring containing one N atom; R b is hydrogen or can be taken together with R a to form a substituted or unsubstituted unsaturated 4, 5, 6, 7 or 8 membered ring containing one N atom; - each R 1 , R 3 , R 4 , and R 6
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally includes one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatoms being selected from the atoms O, S and N;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene can be unsubstituted or substituted with Z;
- R 2 is selected from hydrogen; alkyl; alkenyl; and alkynyl; - R 5 is selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; - SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -
- n is selected from O; 1 or 2;
- B represents a cyclic structure selected from cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; and heterocycle; m is selected from 0; 1 ; 2; 3; 4 and 5;
- R 8 is independently selected from hydrogen; halogen; alkyl; alkenyl; alkynyl; -OH; -
- OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; - NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ;
- alkyl, alkenyl and alkynyl optionally includes one or more heteroatoms, said heteroatoms being selected from the atoms O, S and N;
- each Z is independently selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; - S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; - NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; - NR 12 ;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- each R 12 and R 13 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene or heterocycle-alkynylene;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- R 12 and R 13 can be taken together in order to form a (5-, 6-, or 7- membered) heterocycle which can be unsubstituted or substituted;
- L is independently selected from -0-; -NH-; -NR 10 -; Ci -6 alkylene; Ci- 6 alkenylene; Ci -6 alkynylene; * wherein each of said optionally includes one or more heteroatoms, said heteroatoms being selected from the heteroatoms consisting of S and N, and wherein each of said d ⁇ alkylene, Ci- 6 alkenylene or Ci -6 alkynylene, can be unsubstituted or substituted;
- the compounds have a structure according to formula (AA1 ) or other formulae herein, wherein E 1 is CR 1 , E 2 is NR 2 , and E 3 is CR 3 ; or E 1 is N, E 2 is NR 2 , and E 3 is CR 3 ; or E 1 is CR 1 , E 2 is NR 2 , and E 3 is N; or E 1 is CR 1 , E 2 is O, and E 3 is CR 3 .
- the compounds have a structure according to the formulas (AA2), (AA3), or (AA4):
- the compounds have a structure according to the formulas (AA1 ), (AA2), (AA3), or (AA4), wherein Q is NR b -C(O).
- both R a and R b are hydrogen.
- the present invention therefore provides compounds according to formula (A1 ),
- each dotted line individually represents an optional double bond, wherein maximally two dotted lines selected from the five dotted lines are a double bond; each R 1 , R 3 , R 4 , R 5 and R 6 is independently selected from hydrogen; halogen; -OH; - OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; - NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally includes one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatoms being selected from the atoms O, S and N;
- L is independently selected from being not present; -O-; -NH-; -NR 10 -; Ci- 6 alkenylene; Ci -6 alkynylene;
- B represents a cyclic structure selected from cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; and heterocycle; - m is selected from O; 1 ; 2;3; 4 and 5;
- R 8 is independently selected from hydrogen; halogen; alkyl; alkenyl; alkynyl; -OH; - OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; - NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ; * wherein said alkyl, alkenyl and alkynyl optionally includes one or more heteroatoms, said heteroatoms being selected from the
- alkyl, alkenyl and alkynyl can be unsubstituted or substituted with Z;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- each R 12 and R 13 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene or heterocycle-alkynylene;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- each dotted line individually represents an optional double bond, wherein maximally two dotted lines selected from the five dotted lines are a double bond; each R 1 , R 3 , R 4 , R 5 and R 6 is independently selected from hydrogen; halogen; -OH; - OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; - COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylal
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally includes one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatoms being selected from the atoms O, S and N;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene can be unsubstituted or substituted with Z;
- R 2 is selected from hydrogen; alkyl; alkenyl; and alkynyl; n is selected from O; 1 or 2; - each of X, Y, T, W and V is independently selected from -CZ 1 H-; -CZ 1 -; NR 101 ; -O-; -S- ; or -CO-; wherein at least one of X, Y, T; W or V is selected from -CZ 1 H- or -CZ 1 -;
- L is independently selected from being not present; -O-; -NR 10 -; Ci -6 alkylene; Ci- 6 alkenylene; Ci -6 alkynylene; * wherein each of said Ci -6 alkylene, Ci -6 alkenylene or Ci -6 alkynylene optionally includes one or more heteroatoms, said heteroatoms being selected from the heteroatoms consisting of O, S and N, and wherein each of said Ci -6 alkylene, Ci- 6 alkenylene or can be unsubstituted or substituted;
- B represents a cyclic structure selected from cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; and heterocycle; m is selected from O; 1 ; 2;3; 4 and 5; - R 8 is independently selected from hydrogen; halogen; alkyl; alkenyl; alkynyl; -OH; - OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; - COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ;
- alkyl, alkenyl and alkynyl optionally includes one or more heteroatoms, said heteroatoms being selected from the atoms O, S and N;
- alkyl, alkenyl and alkynyl can be unsubstituted or substituted with Z;
- each Z is independently selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; - S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NR 10 C(O)R 10 ; - NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ; - each Z 1 is independently selected from hydrogen and Z; each R 10 is independently selected from alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle- alkenylene or heterocycle-alkyny
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- each R 12 and R 13 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene or heterocycle-alkynylene;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- the compounds of the invention have a structure according to the formulas (AA1 ), (AA2) (AA3), (AA4), or (A1 ) or any subgroup thereof, whereby V is N. Yet more in particular, the compounds of the invention have a structure according to the formulas (AA1 ), (AA2) (AA3), (AA4), or (A1 ) or any subgroup thereof, whereby T is O. In a still more particular embodiment, the compounds of the invention have a structure according to the formulas (AA1 ), (AA2) (AA3), (AA4), or (A1 ) or any subgroup thereof, whereby V is N and T is O. In another more particular embodiment, the compounds of the invention have a structure according to the formulas (AA1 ), (AA2) (AA3), (AA4), or (A1 ) or any subgroup thereof, whereby W and Y are C.
- the compounds have a structure according to the formulas (AA1 ), (AA2) (AA3), (AA4), or (A1 ) or any subgroup thereof, wherein the dotted lines and X, Y, T, W and V are selected from -CZ 1 H-; -CZ 1 -; - C-; -N-; NR 101 ; -O-; -S-; or -CO-; to form one of the following cycles:
- the compounds have a structure according to the formulas (AA1 ), (AA2) (AA3), (AA4), or (A1 ) or any subgroup thereof, wherein the dotted lines and X, Y, T, W and V are selected from -CZ 1 H-; -CZ 1 -; NR 101 ; -O- ; -S-; or -CO-; to form one of the following cycles:
- the compounds have a structure according to formula (A2), (A2 1 ), (AB2) or (AB2 1 );
- each dotted line individually represents an optional double bond, wherein maximally two dotted lines selected from the five dotted lines are a double bond; each R 1 , R 3 , R 4 , R 5 and R 6 is independently selected from hydrogen; halogen; -OH; - OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally includes one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatoms being selected from the atoms O, S and N;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene can be unsubstituted or substituted with Z;
- R 2 is selected from hydrogen; alkyl; alkenyl; and alkynyl; n is selected from O; 1 or 2; - each of X, Y and W is independently selected from -CZ 1 H-; -CZ 1 -; -C-; -N-; NR 101 ; -0-;
- X, Y or W is selected from -CZ 1 H- or -CZ 1 - or -C- ;
- L is independently selected from being not present; -0-; -NH-; -NR 10 -; Ci -6 alkylene; Ci- 6 alkenylene; Ci -6 alkynylene;
- each of said Ci -6 alkylene, Ci -6 alkenylene or Ci -6 alkynylene optionally includes one or more heteroatoms, said heteroatoms being selected from the heteroatoms consisting of O, S and N, and wherein each of said Ci- 6 alkenylene or Ci -6 alkynylene, can be unsubstituted or substituted;
- Ci -6 alkylene Ci -6 alkenylene or Ci -6 alkynylene
- - B represents a cyclic structure selected from cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; and heterocycle
- m is selected from 0; 1 ; 2;3; 4 and 5;
- R 8 is independently selected from hydrogen; halogen; alkyl; alkenyl; alkynyl; -OH; - OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; - NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ;
- alkyl, alkenyl and alkynyl optionally includes one or more heteroatoms, said heteroatoms being selected from the atoms O, S and N;
- each Z is independently selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; - S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; - NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; -
- each Z 1 is independently selected from hydrogen; alkyl; and Z; each R 10 is independently selected from alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle- alkenylene or heterocycle-alkynylene;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- each R 101 is independently selected from hydrogen and R 10 ;
- each R 11 is independently selected from hydroxyl; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene or heterocycle-alkynylene;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- each R 12 and R 13 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene or heterocycle-alkynylene; *and wherein said alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, arylalkenylene, arylalkynylene, arylalkenylene, arylalkynylene; arylalkenylene, arylalkynylene; arylalkenylene or heterocycle-alkynylene; *and wherein said alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkylene, arylal
- the compounds of the invention are not selected from:
- the compounds have a structure according to formula
- each dotted line individually represents an optional double bond, wherein maximally two dotted lines selected from the five dotted lines are a double bond; each R 1 , R 3 , R 4 , R 5 and R 6 is independently selected from hydrogen; halogen; -OH; - OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; - COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylal
- each of X, Y and W is independently selected from -CZ 1 H-; -CZ 1 -; NR 101 ; -O-; -S-; or - CO-; wherein at least one of X, Y or W is selected from -CZ 1 H- or -CZ 1 -; - L is independently selected from being not present; -O-; -NR 10 -; Ci -6 alkylene; Ci- 6 alkenylene; Ci -6 alkynylene;
- each of said Ci -6 alkylene, Ci -6 alkenylene or Ci -6 alkynylene optionally includes one or more heteroatoms, said heteroatoms being selected from the heteroatoms consisting of O, S and N, and wherein each of said Ci -6 alkylene, Ci- ⁇ slkenylene or can be unsubstituted or substituted;
- Ci -6 alkylene Ci -6 alkenylene or Ci -6 alkynylene
- B represents a cyclic structure selected from cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; and heterocycle; m is selected from 0; 1 ; 2;3; 4 and 5;
- R 8 is independently selected from hydrogen; halogen; alkyl; alkenyl; alkynyl; -OH; - OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy, nitro; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; - COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ;
- alkyl, alkenyl and alkynyl optionally includes one or more heteroatoms, said heteroatoms being selected from the atoms O, S and N;
- each Z is independently selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; - S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy, nitro; -NR 10 C(O)R 10 ; - NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- each R 12 and R 13 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene or heterocycle-alkynylene;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- the compounds of the invention are not selected from:
- 3-lsoxazolecarboxamide N-[2-(1 H-indol-3-yl)ethyl]-5-[[(6-methyl-3- pyridinyl)oxy]methyl]-; * 3-lsoxazolecarboxamide, N-[2-(5-chloro-2,7-dimethyl-1 H-indol-3-yl)ethyl]-5-(4- chlorophenyl)-;
- the compounds have a structure according to formula (A3), (A4), (A4') or (A4)),
- the compounds have a structure according la (AB3), (AB4), (AB4 1 ) or (AB4"),
- the compounds have a structure according to the formulas (AA1 ), (AA2), (AA3), (AA4), (A1 ), (A2), (A2 1 ), (AB2), (AB2 1 ), (A3), (A4), (A4'), (A4"), (AB3), (AB4), (AB4 1 ) or (AB4") or any subgroup thereof, wherein n is 1.
- the compounds have a structure according to the formulas (AA1), (AA2), (AA3), (AA4), (A1 ), (A2), (A2 1 ), (AB2),
- the compounds have a structure according to the formulas (AA1 ), (AA2), (AA3), (AA4), (A1 ),
- the compounds have a structure according to the formulas (AA1), (AA2), (AA3), (AA4), (A1 ), (A2), (A2'), (AB2), (AB2'), (A3), (A4), (A4'), (A4"), (AB3), (AB4), (AB4') or (AB4") or any subgroup thereof,
- B is C 3-8 cycloalkyl or C 6- ioaryl and R 8 is selected from hydrogen, halogen, cyano, Ci-6alkoxy, trifluoromethyl; trifluoromethoxy.
- the compounds have a structure according to the formulas (AA1 ), (AA2), (AA3), (AA4), (A1 ), (A2), (A2'), (AB2), (AB2 1 ), (A3), (A4), (A4 1 ), (A4"), (AB3), (AB4), (AB4 1 ) or (AB4") or any subgroup thereof, whereby the cycle B is phenyl.
- the compounds have a structure according to the formulas (AA1 ), (AA2), (AA3), (AA4), (A1 ), (A2), (A2'), (AB2), (AB2'), (A3), (A4), (A4'), (A4"), (AB3), (AB4), (AB4 1 ) or (AB4") or any subgroup thereof, whereby L is selected from being not present; -O-; -NH-; -NR 10 -; and Ci -6 alkylene, yet more in particular, whereby L is selected from -O-; -NH-; -NR 10 -; and Ci -6 alkylene, and still more in particular, L is Ci -6 alkylene, optionally substituted by one or more substituents each independently selected from halogen; Ci -6 alkyl; haloCi -6 alkyl; haloCi -6 alkyloxy and still more in particular, whereby L is -CH 2 -.
- the compounds have a structure according to the formulas (AA1 ), (AA2), (AA3), (AA4), (A1 ), (A2), (A2'), (AB2), (AB2'), (A3), (A4), (A4'), (A4"), (AB3), (AB4), (AB4 1 ) or (AB4") or any subgroup thereof, whereby L is selected from being not present; -O-; -NR 10 -; and Ci -6 alkylene, yet more in particular, whereby L is selected from -O-; -NR 10 -; and Ci -6 alkylene, and still more in particular, L is Ci.
- the compounds have a structure according to the formulas herein, whereby R 8 is selected from hydrogen and halogen.
- the compounds have a structure according to the formulas herein, whereby R 1 , R 3 , R 4 and R 6 are hydrogen.
- a particular embodiment of the invention relates to compounds with a structure according to formula (A5), (A6), (A5'), (A5"), (A6 1 ) or (A6"):
- Another particular embodiment of the invention relates to compounds with a structure according to formula (A9) or (A10)
- Another particular embodiment of the invention relates to compounds with a structure according to formula (A11 ) or (A12)
- the compounds of the present invention are selected from the list of: N-(2-(5-chloro-1 H-indol-3-yl)ethyl)-5-(3-methoxybenzyl)isoxazole-3- carboxamide; N-(2-(5-chloro-1 H-indol-S-yOethy ⁇ - ⁇ -cyclopentylisoxazole-S-carboxamide;
- a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a compound according to the invention.
- Another aspect of the present invention provides the compounds according to formula (AA1 ), (AA2), (AA3), (AA4), (A1 ), (A2), (A2 1 ), (AB2), (AB2 1 ), (A3), (A4), (A4 1 ), (A4"), (AB3), (AB4), (AB4 1 ), (AB4"), (A5), (A6), (A5 1 ), (A5"), (A6'), (A6"), (A7), (A8), (A9),
- the invention provides the compounds for use a medicine for the prevention or treatment of neurodegenerative disorders, wherein more particularly, the neurodegenerative disorder is selected from Alzheimer's disease, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, frontotemporal dementia, parkinsonism (linked to chromosome 17, FTDP-17), Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann- Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, and multiple system atrophy.
- the neurodegenerative disorder is selected from Alzheimer's disease, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, frontotemporal dementia, parkinsonism (linked to chromosome 17, FTDP-17), Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann- Pick disease, Hallervorden-Spatz syndrome, Down syndrome,
- the present invention also provides for the use of the compounds according to formula (AA1 ), (AA2), (AA3), (AA4), (A1 ), (A2), (A2'), (AB2), (AB2'), (A3), (A4), (A4'), (A4"), (AB3), (AB4), (AB4'), (AB4"), (A5), (A6), (A5'), (A5"), (A6'), (A6"), (A7), (A8), (A9), (A10), (A11 ), (A12) or any subgroup thereof, or all other formulas herein or according to all embodiments described herein, and isomers (in particular stereo-isomers or tautomers), solvates, hydrates, salts (in particular pharmaceutically acceptable salts) or prodrugs thereof, for the manufacture of a medicament for the prevention or treatment of a disorder in an animal, more in particular a mammal or a human.
- isomers in particular stereo-isomers or t
- the invention provides for the use of the compounds as described herein for the manufacture of a medicament for the prevention or treatment of a neurodegenerative disorder in an animal, wherein more particularly, the neurodegenerative disorder is selected from Alzheimer's disease, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, frontotemporal dementia, parkinsonism (linked to chromosome 17, FTDP-17), Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, and multiple system atrophy.
- the neurodegenerative disorder is selected from Alzheimer's disease, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, frontotemporal dementia, parkinsonism (linked to chromosome 17, FTDP-17), Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-
- Another aspect of the invention relates to a method for the prevention or treatment of a disorder in animals, more particularly mammals or humans, by the administration of one or more such compounds according to formula (AA1 ), (AA2), (AA3), (AA4), (A1 ), (A2), (A2'), (AB2), (AB2'), (A3), (A4), (A4'), (A4"), (AB3), (AB4), (AB4'), (AB4"), (A5), (A6), (A5'), (A5"), (A6'), (A6"), (A7), (A8), (A9), (A10), (A1 1 ), (A12) or any subgroup thereof, or all other formulas herein or according to all embodiments described herein, and isomers (in particular stereo-isomers or tautomers), solvates, hydrates, salts (in particular pharmaceutically acceptable salts) or prodrugs thereof to a patient in need thereof.
- isomers in particular stereo-isomers or
- said disorder is a neurodegenerative disorder, wherein more particularly, the neurodegenerative disorder is selected from Alzheimer's disease, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, frontotemporal dementia, parkinsonism (linked to chromosome 17, FTDP-17), Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann- Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, and multiple system atrophy.
- the neurodegenerative disorder is selected from Alzheimer's disease, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, frontotemporal dementia, parkinsonism (linked to chromosome 17, FTDP-17), Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann- Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, and multiple system
- Another aspect of the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising one or more pharmaceutically acceptable carriers or excipients and a therapeutically effective amount of a compound according to formula (AA1 ), (AA2), (AA3), (AA4), (A1 ), (A2), (A2 1 ), (AB2), (AB2 1 ), (A3), (A4), (A4 1 ), (A4"), (AB3), (AB4), (AB4 1 ), (AB4"), (A5), (A5"), (A6), (A5 1 ), (A6 1 ), (A6"), (A7), (A8), (A9), (A10), (A1 1 ), (A12) or any subgroup thereof, or all other formulas herein or according to all embodiments described herein, and isomers (in particular stereo-isomers or tautomers), solvates, hydrates, salts (in particular pharmaceutically acceptable salts) or prodrugs thereof.
- the present invention relates to pharmaceutical compositions
- pharmaceutical compositions comprising the compounds of the invention according to formulae, embodiments and claims herein in admixture with at least a pharmaceutically acceptable carrier, the active compounds preferably being in a concentration range of about 0.1 to 100% by weight.
- the invention further relates to the use of a composition
- a composition comprising (a) one or more compounds of the invention (of formulae, embodiments and claims herein), and (b) one or more drugs known for the (symptomatic) prevention or treatment of neurodegenerative disorders.
- Yet another aspect of the invention provides a method for the preparation of the compounds of the invention which comprises the following steps (with the knowledge that where indole is described, the same counts for the corresponding heterocycles as described herein i.e. aza-indole, indazole, benzoxazole): - reacting a substituted or unsubstituted (1 H-indol-3-yl)methanamine, 2-(1 H-indol-
- the 5 membered ring bears a halogen atom or a -CH 2 LG radical wherein LG is a leaving group with suitable nucleophiles or with derivatives such as boronic acid, stannane or organozinc derivatives.
- alkyl, alkenyl or alkynyl can be restricted to refer to their cyclic or linear subgroups (such as the linear alkyl or cycloalkyl for alkyl).
- the invention relates to the compounds of formula and claims herein being useful as agents having biological activity or as diagnostic agents. Any of the uses mentioned with respect to the present invention may be restricted to a non-medical use, a non-therapeutic use, a non-diagnostic use, or exclusively an in vitro use, or a use related to cells remote from an animal.
- Figure 1 shows the sensitivity of a TAU(301 ) expressing neuroblastoma cell line to retinoic acid-instigated differentiation.
- Figure 2 shows the sensitivity of an ⁇ -synuclein expressing neuroblastoma cell line to paraquat.
- FIG. 3 shows that compound D5 (see table 1 ) reduces pathological TAU-species in-vivo.
- Quantification of Western analyses of TAU and phospho-TAU species of the soluble protein fraction prepared from cortex of all individual mice used in this study (n 10 for each treatment group).
- TAU signals of all individual mice were normalized against neuron specific enolase (NSE) using antibodies (monoclonal anti-NSE antibody, clone 37E4, Abeam) to correct for possible loading control differences.
- the graphs depict the mean normalised TAU signals ⁇ SEM.
- the TAU signals were obtained by using antibodies directed against:
- pan-TAU anti-TAU monoclonal antibody (mAb) HT7, Thermo Scientific; detects all tau species independent of phosphorylation status
- L are directly coupled to each other via a single bond.
- the term "not being present” and “single bond” are synonyms and used interchangeably.
- the invention refers to a compound comprising the following formula wherein L is independently selected from being not present; -
- heteroalkyl refers to a group where one or more carbon atoms are replaced by an oxygen, nitrogen or sulphur atom and thus includes, depending on the group to which is referred, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylene, heteroalkenylene, heteroalkynylene, cycloheteroalkyl, cycloheteroalkenyl, cycloheteroalkynyl, heteroaryl, arylheteroalkyl(ene), heteroarylalkyl(ene), heteroarylheteroalkyl(ene), arylheteroalkenyl(ene), heteroarylalkenyl(ene), heteroarylheteroalkenyl(ene), heteroarylheteroalkenyl(ene), heteroarylheteroalkenyl(ene), heteroarylheteroalkenyl(ene), arylheteroalkenyl(ene), arylhe
- This term therefore comprises, depending on the group to which is referred, as an example alkoxy, alkenyloxy, alkynyloxy, alkyl-O-alkylene, alkenyl-O-alkylene, arylalkoxy, benzyloxy, heterocycle-heteroalkyl, heterocycle-alkoxy, among others.
- alkyl which optionally includes one or more heteroatoms, said heteroatoms being selected from the atoms consisting of O, S, and N therefore refers to heteroalkyl, meaning an alkyl which comprises one or more heteroatoms in the hydrocarbon chain, whereas the heteroatoms may be positioned at the beginning of the hydrocarbon chain, in the hydrocarbon chain or at the end of the hydrocarbon chain.
- heteroalkyl examples include methoxy, methylthio, ethoxy, propoxy, CH 3 -O-CH 2 -, CH 3 - S-CH 2 -, CH 3 -CH 2 -O-CH 2 -, CH 3 -NH-, (CH 3 ) 2 -N-, (CH 3 ) 2 -CH 2 -NH-CH 2 -CH 2 -, among many other examples.
- arylalkylene which optionally includes one or more heteroatoms in the alkylene chain, said heteroatoms being selected from the atoms consisting of O, S, and N
- arylheteroalkylene meaning an arylalkylene which comprises one or more heteroatoms in the hydrocarbon chain, whereas the heteroatoms may be positioned at the beginning of the hydrocarbon chain, in the hydrocarbon chain or at the end of the hydrocarbon chain.
- Arylheteroalkylene thus includes aryloxy, arylalkoxy, aryl-alkyl-NH- and the like and examples are phenyloxy, benzyloxy, aryl-CH 2 -S-CH 2 -, aryl-CH 2 -O-CH 2 -, aryl-NH-CH 2 - among many other examples.
- leaving group means a chemical group which is susceptible to be displaced by a nucleophile or cleaved off or hydrolysed in basic or acidic conditions.
- a leaving group is selected from a halogen atom (e.g., Cl, Br, I) or a sulfonate (e.g., mesylate, tosylate, triflate).
- alkyl as used herein means CrCi 8 normal, secondary, or tertiary, linear or cyclic, branched or straight hydrocarbon with no site of unsaturation.
- alkyl refers to Ci_i
- linear alkyl as used herein means Ci-Ci 8 normal, secondary, or tertiary, linear, branched or straight, hydrocarbon with no site of unsaturation. Examples are methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2-methyl-1-propyl(i-Bu), 2-butyl (s-Bu) 2-methyl- 2-propyl (t-Bu), 1-pentyl (n-pentyl), 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1 -butyl, 2-methyl-1 -butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl- 2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl and 3,3-dimethyl-2-butyl
- cycloalkyl means a monocyclic saturated hydrocarbon monovalent radical having from 3 to 10 carbon atoms, such as for instance cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like, or a C 7- io polycyclic saturated hydrocarbon monovalent radical having from 7 to 10 carbon atoms such as, for instance, norbornyl, fenchyl, trimethyltricycloheptyl or adamantyl.
- alkenyl as used herein is C 2 -Ci 8 normal, secondary or tertiary, linear or cyclic, branched or straight hydrocarbon with at least one site (usually 1 to 3, preferably 1 ) of unsaturation, namely a carbon-carbon, sp2 double bond.
- sites usually 1 to 3, preferably 1
- unsaturation namely a carbon-carbon, sp2 double bond.
- the double bond may be in the cis or trans configuration.
- the term alkenyl refers to C M2 hydrocarbons, yet more in particular to Ci -6 hydrocarbons as further defined herein above.
- linear alkenyl refers to C 2 -Ci 8 normal, secondary or tertiary, linear, branched or straight hydrocarbon with at least one site (usually 1 to 3, preferably 1 ) of unsaturation, namely a carbon-carbon, sp2 double bond.
- sites usually 1 to 3, preferably 1
- unsaturation namely a carbon-carbon, sp2 double bond.
- the double bond may be in the cis or trans configuration.
- cycloalkenyl refers to C 2 -C 18 normal, secondary or tertiary, cyclic hydrocarbon with at least one site (usually 1 to 3, preferably 1 ) of unsaturation, namely a carbon-carbon, sp2 double bond. Examples include, but are not limited to: cyclopentenyl (-C 5 H 7 ) and cyclohexenyl (-C 6 H 9 ).
- the double bond may be in the cis or trans configuration.
- alkynyl refers to C 2 -Ci 8 normal, secondary, tertiary, linear or cyclic, branched or straight hydrocarbon with at least one site (usually 1 to 3, preferably 1 ) of unsaturation, namely a carbon-carbon, sp triple bond. Examples include, but are not limited to: acetylenic (-C ⁇ CH) and propargyl (-CH 2 C ⁇ CH).
- alkenyl refers to C M2 hydrocarbons, yet more in particular to Ci -6 hydrocarbons as further defined herein above.
- linear alkynyl refers to C 2 -Ci 8 normal, secondary, tertiary, linear, branched or straight hydrocarbon with at least one site (usually 1 to 3, preferably 1 ) of unsaturation, namely a carbon-carbon, sp triple bond.
- sites usually 1 to 3, preferably 1
- unsaturation namely a carbon-carbon, sp triple bond.
- examples include, but are not limited to: acetylenic (-C ⁇ CH) and propargyl (-CH 2 C ⁇ CH).
- cycloalkynyl refers to C 2 -Ci 8 normal, secondary, tertiary, cyclic hydrocarbon with at least one site (usually 1 to 3, preferably 1 ) of unsaturation, namely a carbon-carbon, sp triple bond. Examples include, but are not limited to: cyclohex-1-yne and ethylene-cyclohex-1-yne.
- alkylene each refer to a saturated, branched or straight chain hydrocarbon radical of 1-18 carbon atoms (more in particular 1-12 or 1-6 carbon atoms), and having two monovalent radical centers derived by the removal of two hydrogen atoms from the same or two different carbon atoms of a parent alkane.
- Typical alkylene radicals include, but are not limited to: methylene (-CH 2 -) 1 ,2-ethyl (-CH 2 CH 2 -), 1 ,3-propyl (-CH 2 CH 2 CH 2 -), 1 ,4-butyl (-CH 2 CH 2 CH 2 CH 2 -), and the like.
- aryl as used herein means a aromatic hydrocarbon radical of 6-20 carbon atoms derived by the removal of hydrogen from a carbon atom of a parent aromatic ring system.
- Typical aryl groups include, but are not limited to 1 ring, or 2 or 3 rings fused together, radicals derived from benzene, naphthalene, anthracene, biphenyl, and the like.
- parent aromatic ring system means a monocyclic aromatic ring system or a bi- or tricyclic ring system of which at least one ring is aromatic.
- typical aryl groups include, but are not limited to 1 ring, or 2 or 3 rings fused together, radicals derived from benzene, naphthalene, anthracene, biphenyl, 2,3-dihydro-1 H-indenyl, 5,6,7,8-tetrahydronaphthalenyl, 1 ,2,6,7,8,8a-hexahydroacenaphthylenyl, 1 ,2-dihydroacenaphthylenyl, and the like.
- Arylalkylene refers to an alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with an aryl radical.
- Typical arylalkylene groups include, but are not limited to, benzyl, 2-phenylethan-1-yl, 2-phenylethen-1-yl, naphthylmethyl, 2-naphthylethan-1-yl, 2- naphthylethen-1-yl, naphthobenzyl, 2-naphthophenylethan-1-yl and the like.
- the arylalkylene group comprises 6 to 20 carbon atoms, e.g.
- alkylene moiety of the arylalkylene group is 1 to 6 carbon atoms and the aryl moiety is 5 to 14 carbon atoms.
- Arylalkenylene refers to an alkenylene radical in which one of the hydrogen atoms bonded to a carbon atom, is replaced with an aryl radical.
- the arylalkenylene group comprises 6 to 20 carbon atoms, e.g. the alkenylene moiety of the arylalkenylene group is 1 to 6 carbon atoms and the aryl moiety is 5 to 14 carbon atoms.
- Arylalkynylene refers to an alkynyl radical in which one of the hydrogen atoms bonded to a carbon atom, is replaced with an aryl radical.
- the arylalkynylene group comprises 6 to 20 carbon atoms, e.g. the alkynylene moiety of the arylalkynylene group is 1 to 6 carbon atoms and the aryl moiety is 5 to 14 carbon atoms.
- heterocycle as used herein means a saturated, unsaturated or aromatic ring system including at least one N, O, S, or P. Heterocycle thus include heteroaryl groups.
- Heterocycle as used herein includes by way of example and not limitation these heterocycles described in Paquette, Leo A. “Principles of Modern Heterocyclic Chemistry” (W.A. Benjamin, New York, 1968), particularly Chapters 1 , 3, 4, 6, 7, and 9; "The Chemistry of Heterocyclic Compounds, A series of Monographs” (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; Katritzky, Alan R., Rees, CW. and Scriven, E. “Comprehensive Heterocyclic Chemistry” (Pergamon Press, 1996); and J. Am. Chem. Soc. (1960) 82:5566.
- the term means pyridyl, dihydroypyridyl, tetrahydropyridyl (piperidyl), thiazolyl, tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2- pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, bis-tetrahydrofuranyl, tetrahydropyranyl, bis- tetrahydropyranyl, tetrahydroquinolinyl,
- Heterocycle-alkylene refers to an alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with a heterocycle radical.
- An example of a heterocycle-alkylene group is 2- pyridyl-methylene.
- the heterocycle-alkylene group comprises 6 to 20 carbon atoms, e.g. the alkylene moiety of the heterocycle-alkyl group is 1 to 6 carbon atoms and the heterocycle moiety is 5 to 14 carbon atoms.
- Heterocycle-alkenylene refers to an alkenyl radical in which one of the hydrogen atoms bonded to a carbon atom, is replaced with an heterocycle radical.
- the heterocycle-alkenylene group comprises 6 to 20 carbon atoms, e.g. the alkenylene moiety of the heterocycle-alkenylene group is 1 to 6 carbon atoms and the heterocycle moiety is 5 to 14 carbon atoms.
- Heterocycle-alkynylene refers to an alkynylene radical in which one of the hydrogen atoms bonded to a carbon atom, is replaced with a heterocycle radical.
- the heterocycle-alkynylene group comprises 6 to 20 carbon atoms, e.g. the alkynylene moiety of the heterocycle-alkynylene group is 1 to 6 carbon atoms and the heterocycle moiety is 5 to 14 carbon atoms.
- Heteroaryl means an aromatic ring system including at least one N, O, S, or P.
- heteroaryl include but are not limited to pyridyl, dihydropyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, s-triazinyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, furanyl, thiofuranyl, thienyl, and pyrrolyl.
- Heteroaryl-alkylene refers to an alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp3 carbon atom, is replaced with a heterocycle radical.
- An example of a heteroaryl-alkylene group is 2- pyridyl-methylene.
- the heteroaryl-alkylene group comprises 6 to 20 carbon atoms, e.g. the alkylene moiety of the heteroaryl-alkylene group is 1 to 6 carbon atoms and the heteroaryl moiety is 5 to 14 carbon atoms.
- Heteroaryl-alkenylene refers to an alkenyl radical in which one of the hydrogen atoms bonded to a carbon atom, is replaced with an heteroaryl radical.
- the heteroaryl-alkenylene group comprises 6 to 20 carbon atoms, e.g. the alkenylene moiety of the heteroaryl-alkenylene group is 1 to 6 carbon atoms and the heteroaryl moiety is 5 to
- Heteroaryl-alkynylene refers to an alkynyl radical in which one of the hydrogen atoms bonded to a carbon atom, is replaced with a heteroaryl radical.
- the heteroaryl-alkynylene group comprises 6 to 20 carbon atoms, e.g. the alkynylene moiety of the heteroaryl-alkynylene group is 1 to 6 carbon atoms and the heteroaryl moiety is 5 to
- carbon bonded heterocyclic rings are bonded at position 2, 3,
- carbon bonded heterocycles include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3- pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5- pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4- thiazolyl, or 5-thiazolyl.
- nitrogen bonded heterocyclic rings are bonded at position 1 of an aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3- pyrazoline, piperidine, piperazine, indole, indoline, 1 H-indazole, position 2 of a isoindole, or isoindoline, position 4 of a morpholine, and position 9 of a carbazole, or ⁇ -carboline.
- nitrogen bonded heterocycles include 1-aziridyl, 1-azetedyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.
- alkoxy As used herein and unless otherwise stated, the terms "alkoxy”, “cycloalkoxy”,
- aryloxy, “arylalkyloxy”, “oxyheterocycle ring”, “thio-alkyl”, “thio-cycloalkyl”, “arylthio”, “arylalkylthio” and “thioheterocycle” refer to substituents wherein an alkyl radical, respectively a cycloalkyl, aryl, arylalkyl or heterocycle radical (each of them such as defined herein), are attached to an oxygen atom or a sulfur atom through a single bond, such as but not limited to methoxy, ethoxy, propoxy, butoxy, thioethyl, thiomethyl, phenyloxy, benzyloxy, mercaptobenzyl and the like.
- alkenyl and alkynyl radicals in stead of alkyl.
- halogen means any atom selected from the group consisting of fluorine, chlorine, bromine and iodine.
- substituted any atom selected from the group consisting of fluorine, chlorine, bromine and iodine.
- substituted it is meant to indicate that one or more hydrogens on the atom, or group indicated in the expression using "substituted” is replaced with one or more group each independently selected from halogen; alkyl; alkenyl; alkynyl; -OH; -OR 10 ; -SH; -SR 10 ; - S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; - NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; --
- Any substituent designation that is found in more than one site in a compound of this invention shall be independently selected. Substituents optionally are designated with or without bonds. Regardless of bond indications, if a substituent is polyvalent (based on its position in the structure referred to), then any and all possible orientations of the substituent are intended.
- stereoisomer refers to all possible different isomeric as well as conformational forms which the compounds of structural formula herein may possess, in particular all possible stereochemical ⁇ and conformationally isomeric forms, all diastereomers, enantiomers and/or conformers of the basic molecular structure. Some compounds of the present invention may exist in different tautomeric forms, all of the latter being included within the scope of the present invention.
- enantiomer means each individual optically active form of a compound of the invention, having an optical purity or enantiomeric excess (as determined by methods standard in the art) of at least 80% (i.e.
- solvate includes any combination which may be formed by a derivative of this invention with a suitable inorganic solvent (e.g. hydrates) or organic solvent, such as but not limited to alcohols, ketones, esters, ethers, nitriles and the like.
- a suitable inorganic solvent e.g. hydrates
- organic solvent such as but not limited to alcohols, ketones, esters, ethers, nitriles and the like.
- the present invention encompasses compounds of formula (AA1 ) or any subgroup thereof, wherein, each dotted line individually represents an optional double bond, wherein maximally two dotted lines selected from the five dotted lines are a double bond;
- E 1 is independently selected from CR 1 ; and N; preferably E 1 is CR 1 ;
- E 2 is independently selected from NR 2 ; and O; preferably E 2 is NR 2 ; - E 3 is independently selected from CR 3 ; and N; preferably E 3 is CR 3 ;
- Q is independently selected from NR b -C(O); or C(O)NH; preferably Q is selected NR b -C(O);
- R a is hydrogen or can be taken together with R b to form a substituted or unsubstituted unsaturated 4, 5, 6, 7 or 8 membered ring containing one N atom, for example a piperidine ring; preferably R a is hydrogen;
- R b is hydrogen or can be taken together with R a to form a substituted or unsubstituted unsaturated 4, 5, 6, 7 or 8 membered ring containing one N atom, for example a piperidine ring; preferably R b is hydrogen;
- R 1 is selected from hydrogen; halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10
- R 4 is selected from hydrogen; halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; - COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene;
- R 6 is selected from hydrogen; halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; - COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene;
- R 2 is selected from hydrogen; alkyl; alkenyl; and alkynyl; preferably R 2 is selected from hydrogen; C 1-6 alkyl; C 3-8 cycloalkyl; Ci -6 alkenyl; and Ci -6 alkynyl; preferably R 2 is selected from hydrogen, Ci -6 alkyl, or C 3-8 cycloalkyl; preferably R 2 is hydrogen; R 5 is selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; - NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ;
- R 8 cycloalkyl; C 2-6 alkenyl and C 2-6 alkynyl can be unsubstituted or substituted with Z; preferably R 8 is independently selected from hydrogen; halogen; Ci- ⁇ alkyl; C 3-8 cycloalkyl; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; - NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; - C(O)NR 12 R 13 ; -
- C6-ioarylC 2-6 alkynylene, heterocycle-d-ealkylene, heterocycle-C 2-6 C 2- 6alkenylene or heterocycle-C 2-6 alkynylene optionally include one or more heteroatoms in the Ci -6 alkyl(ene), C 3-8 cycloalkyl(ene), C 2-6 alkenyl(ene) or C 2-6 alkynyl(ene) moiety, said heteroatom selected from O, S and N; wherein a carbon atom or heteroatom of said Ci -6 alkyl, C 3-8 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6 -ioaryl, heterocycle, C 6 -ioarylCi -6 alkylene, C 6 -ioarylC 2-6 alkenylene, C 6 -ioarylC 2-6 alkynylene, heterocycle- Ci -6 alkylene, heterocycle-C 2-6 alkenylene or heterocycle-
- each R 10 is independently selected from Ci -6 alkyl; C 3-8 cycloalkyl; C 6- ioaryl; or heterocycle; preferably each R 10 is independently selected from Ci -6 alkyl; or C 6- ioaryl; preferably each R 10 is Ci -6 alkyl; each R 101 is independently selected from hydrogen and R 10 ; each R 11 is independently selected from hydroxyl; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene or heterocycle-alkynylene; and wherein said alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle- alkylene, heterocycle-alkenylene or heterocycle-alkynylene; and wherein said alkyl, alkenyl
- R 11 is independently selected from hydroxyl; Ci -6 alkyl, C 3-8 cycloalkyl; C 6- 10 aryl, heterocycle, C 6 -ioarylCi-6alkylene, heterocycle-Ci-ealkylene; preferably R 11 is independently selected from hydroxyl; C 1-6 alkyl, C 3-8 cycloalkyl; C 6 -ioaryl, heterocycle, preferably R 11 is independently selected from hydroxyl; Ci -6 alkyl, or C 6 -ioaryl, preferably R 11 is independently selected from hydroxyl or
- each R 12 and R 13 can be taken together in order to form a (5-, 6-, or 7- membered) heterocycle which can be unsubstituted or substituted; preferably each R 12 and R 13 is independently selected from hydrogen; Ci -6 alkyl, C 3 - 8 cycloalkyl; C 6 -ioaryl, heterocycle, C6-ioarylCi -6 alkylene, heterocycle-d-ealkylene; preferably each R 12 and R 13 is independently selected from hydrogen; C 1-6 alkyl, C 3-8 cycloalkyl;
- the present invention encompasses compounds of formula (AA1 ) or any subgroup thereof, wherein,
- E 1 is CR 1 ;
- E 2 is NR 2 ;
- E 3 is CR 3 ;
- Q is selected NR b -C(O); R a is hydrogen;
- R b is hydrogen;
- R 1 is selected from hydrogen; halogen; -OH; -OR 10 ; -SH; -SR 10 ; trifluoromethyl; trifluoromethoxy; nitro; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; C 1-6 alkyl; C 3-8 cycloalkyl;
- C 2 - 6 alkynyl, C 6- ioaryl can be unsubstituted or substituted with Z;
- R 3 is selected from hydrogen; halogen; -OH; -OR 10 ; -SH; -SR 10 ; trifluoromethyl; trifluoromethoxy; nitro; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; C 1-6 alkyl; C 3-8 cycloalkyl;
- C 2-6 alkynyl, C 6 -ioaryl can be unsubstituted or substituted with Z;
- R 4 is selected from hydrogen; halogen; -OH; -OR 10 ; -SH; -SR 10 ; trifluoromethyl; trifluoromethoxy; nitro; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; C 1-6 alkyl; C 3-8 cycloalkyl;
- C 2-6 alkynyl, C 6- ioaryl can be unsubstituted or substituted with Z;
- R 6 is selected from hydrogen; halogen; -OH; -OR 10 ; -SH; -SR 10 ; trifluoromethyl; trifluoromethoxy; nitro; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; C 1-6 alkyl; C 3-8 cycloalkyl; C 2-6 alkenyl; C 2-6 alkynyl; C 6- ioaryl; wherein said Ci -6 alkyl, C 3-8 cycloalkyl, C 2 -6alkenyl,
- C 2-6 alkynyl, C 6- ioaryl can be unsubstituted or substituted with Z;
- R 2 is selected from hydrogen; d- ⁇ alkyl; C 3-6 cycloalkyl; Ci-6alkenyl; and Ci -6 alkynyl;
- R 5 is selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; trifluoromethyl; trifluoromethoxy; nitro; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; C 1-6 alkyl; C 3-8 cycloalkyl; C 2-6 alkenyl; C 2 - 6 alkynyl; C 6 -ioaryl; wherein said Ci -6 alkyl, C 3-8 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6- ioaryl, can be unsubstituted or substituted with Z; n is 1 or 2, preferably n is 1 ;
- B is selected from C 3-8 cycloalkyl; C 5 - 8 cycloalkenyl; C 6- ioaryl; or heterocycle; preferably B is selected from C 3-8 cycloalkyl; C 6- ioaryl; or pyridyl, dihydroypyridyl, piperidyl, thiazolyl, tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2- pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, bis
- R 8 is independently selected from hydrogen; halogen; Ci- ⁇ alkyl; C 3- 8cycloalkyl; C 2- 6alkenyl; C 2 - 6 alkynyl; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; - NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ; - C(O)R 11 ; wherein said Ci -6 alkyl, C 3- 8cycloal
- C6-ioarylC 2-6 alkynylene, heterocycle-d-ealkylene, heterocycle-C 2-6 C 2- 6alkenylene or heterocycle-C 2-6 alkynylene optionally include one or more heteroatoms in the Ci -6 alkyl(ene), C 3-8 cycloalkyl(ene), C 2-6 alkenyl(ene) or C 2-6 alkynyl(ene) moiety, said heteroatom selected from O, S and N; wherein a carbon atom or heteroatom of said Ci -6 alkyl, C 3-8 cycloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 6 -ioaryl, heterocycle, C 6 -ioarylCi -6 alkylene, C 6 -ioarylC 2-6 alkenylene, C 6 -ioarylC 2-6 alkynylene, heterocycle- Ci -6 alkylene, heterocycle-C 2-6 alkenylene or heterocycle-
- L is independently selected from -0-; -NH-; -NR 10 -; Ci -6 alkylene; Ci -6 alkenylene; Ci- 6 alkynylene; X, Y, T, W and V form with the dotted lines one of the cycles having one of the structural formula (Ia), (Na), (Ilia), (IVa), (Va), (Via), (Vila), (Villa), (IXa), or more particularly form with the dotted lines one of the cycles having one of the structural formula (Ia) or (Na), or (NIa), or wherein L is a single bond; and X, Y, T, W and V form with the dotted lines a cycle of formula (Ilia) , wherein the left side of the formula (Ia), (Ha), (Ilia), (IVa), (Va), (Via), (Vila), (Villa), (IXa), is attached to Q and the right side thereof is attached to L.
- the present invention encompasses compounds of formula (A1 ) or any subgroup thereof wherein,
- R 1 is selected from hydrogen; halogen; -OH; -OR 10 ; -SH; -SR 10 ; trifluoromethyl; trifluoromethoxy; nitro; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; C 1-6 alkyl; C 3-6 cycloalkyl; C 6 -ioaryl; wherein said Ci -6 alkyl, C 3-6 cycloalkyl, or C ⁇ -ioaryl, can be unsubstituted or substituted with Z; R 3 is selected from hydrogen; halogen; -OH; -OR 10 ; -SH; -SR 10 ; trifluoromethyl; trifluoromethoxy; nitro; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; C 1-6 alkyl; C 3-6 cycloalkyl;
- Ci -6 alkyl, C 3 - 6 cycloalkyl, or C 6 -ioaryl can be unsubstituted or substituted with Z;
- R 4 is selected from hydrogen; halogen; -OH; -OR 10 ; -SH; -SR 10 ; trifluoromethyl; trifluoromethoxy; nitro; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; C 1-6 alkyl; C 3-6 cycloalkyl;
- Ci -6 alkyl, C 3-6 Cy cloa I kyl, or C 6 -ioaryl can be unsubstituted or substituted with Z;
- R 6 is selected from hydrogen; halogen; -OH; -OR 10 ; -SH; -SR 10 ; trifluoromethyl; trifluoromethoxy; nitro; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; C 1-6 alkyl; C 3-6 cycloalkyl;
- Ci -6 alkyl, C 3-6 cycloalkyl, or C ⁇ -ioaryl can be unsubstituted or substituted with Z;
- R 2 is selected from hydrogen or Ci -6 alkyl
- R 5 is selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; trifluoromethyl; trifluoromethoxy; nitro; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; C 1-6 alkyl; C 3-6 cycloalkyl; C 6-10 aryl; wherein said
- Ci -6 alkyl, C 3-6 cycloalkyl, or C 6- ioaryl can be unsubstituted or substituted with Z; n is 1 ;
- B is selected from C 3-8 cycloalkyl; C 6- ioaryl; or pyridyl, dihydroypyridyl, piperidyl, thiazolyl, tetrahydrothiophenyl, sulfur oxidized tetrahydrothiophenyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, thianaphthalenyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2- pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, bis-tetrahydrofuranyl, tetrahydropyranyl, bis- tetrahydropyranyl, tetrahydroquinolin
- R 8 is independently selected from hydrogen; halogen; Ci- ⁇ alkyl; C 3-6 cycloalkyl; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -
- Ci- ⁇ alkyl or C 3- 6cycloalkyl can be unsubstituted or substituted with Z; each Z is independently selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ;
- each Z 1 is independently selected from hydrogen; alkyl; or Z; preferably each Z 1 is independently selected from hydrogen; Ci -6 alkyl; C 3-6 cycloalkyl; or Z; preferably each Z 1 is independently selected from hydrogen; Ci -6 alkyl; or Z; preferably each Z 1 is independently selected from hydrogen; or Z; each R 10 is independently selected from Ci -6 alkyl; C 3-6 cycloalkyl; C 6- ioaryl; heterocycle;
- each R 101 is independently selected from hydrogen and R 10 ;
- R 11 is independently selected from hydroxyl; d- ⁇ alkyl, C 3-6 cycloalkyl, C 6 -ioaryl, heterocycle, C6-ioarylCi-6alkylene, heterocycle-d-ealkylene; each R 12 and R 13 is independently selected from hydrogen; Ci -6 alkyl, C 3-6 cycloalkyl,
- L is independently selected from -0-; -NH-; -NR 10 -; Ci -6 alkylene; and X, Y, T, W and V form with the dotted lines one of the cycles having one of the structural formula (Ia), (Ha),
- R 1 is selected from hydrogen; halogen; -OH; -OR 10 ; trifluoromethyl; trifluoromethoxy; nitro;
- R 3 is selected from hydrogen; halogen; -OH; -OR 10 ; trifluoromethyl; trifluoromethoxy, nitro; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; C 1-6 alkyl; C 3-6 cycloalkyl; C 6 -i 0 aryl;
- R 4 is selected from hydrogen; halogen; -OH; -OR 10 ; trifluoromethyl; trifluoromethoxy; nitro;
- R 6 is selected from hydrogen; halogen; -OH; -OR 10 ; trifluoromethyl; trifluoromethoxy; nitro;
- -NR 12 R 13 -cyano; -COOH; -COOR 10 ; C 1-6 alkyl; C 3-6 cycloalkyl; C 6 -i 0 aryl; R 2 is hydrogen; R 5 is selected from halogen; -OH; -OR 10 ; trifluoromethyl; trifluoromethoxy; nitro; -NR 12 R 13 ;
- B is selected from C 3-6 cycloalkyl; C 6- ioaryl; or pyridyl, dihydroypyridyl, piperidyl, thiazolyl, tetrahydrothiophenyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4- piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, octahydroisoquinolinyl, azocinyl
- R 8 is independently selected from hydrogen; halogen; d- ⁇ alkyl; C 3- 6cycloalkyl; -OH; -OR 10 ; -SH; -SR 10 ; -S(O) 2 R 11 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NR 10 C(O)R 10 ;
- each Z is independently selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; trifluoromethyl; trifluoromethoxy; nitro; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; each Z 1 is independently selected from hydrogen; alkyl; or Z; preferably each Z 1 is independently selected from hydrogen; Ci -6 alkyl; C 3-6 cycloalkyl; or Z; preferably each Z 1 is independently selected from hydrogen; Ci -6 alkyl; or Z; preferably each Z 1 is independently selected from hydrogen; or Z; each R 10 is independently selected from C 1-6 alkyl; C 3-6 cycloalkyl; C 6- ioaryl; or heterocycle; each R 101 is independently selected from hydrogen and R 10 ;
- R 11 is independently selected from hydroxyl; Ci-6alkyl, C 3-6 cycloalkyl, C 6 -ioaryl, heterocycle, each R 12 and R 13 is independently selected from hydrogen; Ci -6 alkyl, C 3-6 cycloalkyl,
- C 6 -ioaryl, heterocycle, L is independently selected from -O-; or Ci -6 alkylene; and X, Y, T, W and V form with the dotted lines one of the cycles having one of the structural formula (Ia), (Na), (Ilia), (IVa), (Va), (Via), (Vila), (Villa), (IXa), or wherein L is a single bond; and X, Y, T, W and V form with the dotted lines a cycle of formula (Ilia) , wherein the left side of the formula (Ia), (Na), (Ilia), (IVa), (Va), (Via), (Vila), (Villa), (IXa), is attached to Q and the right side thereof is attached to L.
- the present invention encompasses compounds of formula (A1 ) or any subgroup thereof wherein, R 1 is selected from hydrogen; halogen; d- ⁇ alkyl; R 3 is selected from hydrogen; halogen; Ci -6 alkyl; R 4 is selected from hydrogen; halogen; Ci -6 alkyl; R 6 is selected from hydrogen; halogen; Ci -6 alkyl; R 2 is hydrogen; R 5 is selected from halogen or Ci -6 alkyl; n is 1 ; B is selected from C 3- 6cycloalkyl; phenyl, naphthyl, pyridyl, piperidyl, thiazolyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4- piperid
- the present invention encompasses compounds of formula (A1 ) or any subgroup thereof wherein, R 1 is hydrogen; R 3 is hydrogen; R 4 is hydrogen; R 6 is hydrogen; R 2 is hydrogen; R 5 is selected from halogen or Ci -6 alkyl; n is 1 ; B is selected from C3-6cycloalkyl; phenyl, naphthyl, pyridyl, piperidyl, thiazolyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, benzofuranyl, indolyl, indolenyl, quinolinyl, isoquinolinyl, benzimidazolyl, piperidinyl, 4-piperidonyl, pyrrolidinyl, 2-pyrrolidonyl, pyrrolinyl, triazinyl, pyranyl, isobenzofuranyl, 2H-pyrrolyl,
- the present invention also encompasses a pharmaceutical composition
- a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a compound according to formula (AA1 ) or any subgroup thereof or a stereoisomer, enantiomer or tautomer thereof.
- the present invention also encompasses a pharmaceutical composition
- a pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and a therapeutically effective amount of a compound according to formula (AA1 ) or any subgroup thereof or a stereoisomer, enantiomer or tautomer thereof, wherein, each dotted line individually represents an optional double bond, wherein maximally two dotted lines selected from the five dotted lines are a double bond;
- E 1 is independently selected from CR 1 ; and N;
- E 2 is independently selected from NR 2 ; and O;
- E 3 is independently selected from CR 3 ; and N;
- - Q is independently selected from NR b -C(O); and C(O)NH;
- R a is hydrogen or can be taken together with R b to form a substituted or unsubstituted unsaturated 4, 5, 6, 7 or 8 membered ring containing one N atom
- R b is hydrogen or can be taken together with R a to form a substituted or unsubstituted unsaturated 4, 5, 6, 7 or 8 membered ring containing one N atom
- R 1 is independently selected from hydrogen; halogen; -OH; -OR 10 ; -SH; -SR 10 ; - S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ; alkyl; alkenyl; and alkynyl; each R 3 , R 4 , and R 6 is independently selected from hydrogen; halogen; -OH; -OR 10 ; - SH;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally includes one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatoms being selected from the atoms
- n is selected from O; 1 or 2;
- B represents a cyclic structure selected from cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; and heterocycle; - m is selected from O; 1 ; 2; 3; 4 and 5;
- R 8 is independently selected from hydrogen; halogen; alkyl; alkenyl; alkynyl; -OH;
- alkyl, alkenyl and alkynyl can be unsubstituted or substituted with Z;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- each R 101 is independently selected from hydrogen and R 10 ; each R 11 is independently selected from hydroxyl; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene or heterocycle-alkynylene;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- each of said Ci- 6 alkylene, Ci -6 alkenylene or Ci -6 alkynylene optionally includes one or more heteroatoms, said heteroatoms being selected from the heteroatoms consisting of S and N, and wherein each of said Ci -6 alkylene, can be unsubstituted or substituted;
- Ci -6 alkylene Ci -6 alkenylene or Ci- 6 alkynylene
- each of X, Y, T, W and V is independently selected from -CZ 1 H-; -CZ 1 -; -C-; - N-; NR 101 ; -O-; -S-; or -CO-; and form with the dotted lines one of the cycles having one of the structural formula (Ia), (Na), (Ilia), (IVa), (Va), (Via), (Vila), (Villa), (IXa), (Xa),
- Va (Vi), (Via), (Vila), (Villa), (IXa), (Xa), (XIa), (XIIa), (XIIIa), (XIVa), (XVa), (XVIa), (XVIIa), (XVIIIa), (XIXa), (XXa), (XXIa), (XXIIa), (XXIIIa), (XXIVa) is attached to Q and the right side thereof is attached to L.
- the present invention also encompasses compounds of formula (AA1 ) or any subgroup thereof or a stereoisomer, enantiomer, tautomer, solvate, hydrate, salt or prodrug thereof for use as a medicine.
- the present invention also encompasses compounds of formula (AA1 ) or any subgroup thereof or a stereoisomer, enantiomer, tautomer, solvate, hydrate, salt or prodrug thereof for use as a medicine for the prevention or treatment of neurodegenerative disorders, wherein, each dotted line individually represents an optional double bond, wherein maximally two dotted lines selected from the five dotted lines are a double bond;
- E 1 is independently selected from CR 1 ; and N;
- E 2 is independently selected from NR 2 ; and O;
- E 3 is independently selected from CR 3 ; and N;
- R a is hydrogen or can be taken together with R b to form a substituted or unsubstituted 4, 5, 6, 7 or 8 membered ring containing one N atom, preferably a piperidine ring;
- R b is hydrogen or can be taken together with R a to form a substituted or unsubstituted 4, 5, 6, 7 or 8 membered ring containing one N atom, preferably a piperidine ring;
- - Q is independently selected from NR b -C(O); C(O); and C(O)NH; each R 1 , R 3 , R 4 , and R 6 is independently selected from hydrogen; halogen; -OH; - OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; - NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ; alkyl; alkenyl;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally includes one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatoms being selected from the atoms O, S and N;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene can be unsubstituted or substituted with Z;
- - R 5 is independently selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; - S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; - NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; - NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally includes one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatoms being selected from the atoms O, S and N;
- L is independently selected from being not present; -O-; -NH-; -NR 10 -; Ci- 6 alkenylene; Ci -6 alkynylene;
- each of said optionally includes one or more heteroatoms, said heteroatoms being selected from the heteroatoms consisting of O, S and N, and wherein each of said d ⁇ alkylene, Ci- 6 alkenylene or Ci -6 alkynylene, can be unsubstituted or substituted; * and wherein a carbon atom or heteroatom of said or
- B represents a cyclic structure selected from cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; and heterocycle; m is selected from 0; 1 ; 2; 3; 4 and 5; - R 8 is independently selected from hydrogen; halogen; alkyl; alkenyl; alkynyl; -OH; -
- OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -
- alkyl, alkenyl and alkynyl optionally includes one or more heteroatoms, said heteroatoms being selected from the atoms O, S and N;
- alkyl, alkenyl and alkynyl can be unsubstituted or substituted with Z;
- each Z is independently selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; - S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; - NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; - NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -
- each Z 1 is independently selected from hydrogen; alkyl; and Z; - each R 10 is independently selected from alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle- alkenylene or heterocycle-alkynylene;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- each R 101 is independently selected from hydrogen and R 10 ; each R 11 is independently selected from hydroxyl; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene or heterocycle-alkynylene;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- each R 12 and R 13 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene or heterocycle-alkynylene;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- R 12 and R 13 can be taken together in order to form a (5-, 6-, or 7- membered) heterocycle which can be unsubstituted or substituted.
- the present invention also encompasses compounds of formula (AA1 ) or any subgroup thereof or a stereoisomer, enantiomer, tautomer, solvate, hydrate, salt or prodrug thereof for use as a medicine for the prevention or treatment of neurodegenerative disorders, wherein, each dotted line individually represents an optional double bond, wherein maximally two dotted lines selected from the five dotted lines are a double bond; E 1 is independently selected from CR 1 ; and N;
- E 2 is independently selected from NR 2 ; and O;
- E 3 is independently selected from CR 3 ; and N;
- - Q is independently selected from NR b -C(O); and C(O)NH;
- R a is hydrogen or can be taken together with R b to form a substituted or unsubstituted unsaturated 4, 5, 6, 7 or 8 membered ring containing one N atom;
- R b is hydrogen or can be taken together with R a to form a substituted or unsubstituted unsaturated 4, 5, 6, 7 or 8 membered ring containing one N atom; each R 1 , R 3 , R 4 , and R 6 is independently selected from hydrogen; halogen; -OH;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally includes one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatoms being selected from the atoms O, S and N;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene can be unsubstituted or substituted with Z;
- R 2 is selected from hydrogen; alkyl; alkenyl; and alkynyl;
- - R 5 is selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; - NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally includes one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatoms being selected from the atoms O, S and N;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene can be unsubstituted or substituted with Z;
- L is independently selected from being not present, -0-; -NH-; -NR 10 -; Ci -6 alkylene; Ci- 6 alkenylene; Ci -6 alkynylene;
- each of said Ci -6 alkylene, Ci -6 alkenylene or Ci -6 alkynylene optionally includes one or more heteroatoms, said heteroatoms being selected from the heteroatoms consisting of O, S and N, and wherein each of said can be unsubstituted or substituted;
- Ci -6 alkylene Ci -6 alkenylene or Ci -6 alkynylene
- B represents a cyclic structure selected from cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; and heterocycle; m is selected from O; 1 ; 2; 3; 4 and 5;
- R 8 is independently selected from hydrogen; halogen; alkyl; alkenyl; alkynyl; -OH;
- alkyl, alkenyl and alkynyl optionally includes one or more heteroatoms, said heteroatoms being selected from the atoms O, S and N;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- each R 101 is independently selected from hydrogen and R 10 ; each R 11 is independently selected from hydroxyl; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene or heterocycle-alkynylene;
- each R 12 and R 13 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene or heterocycle-alkynylene;
- Another aspect of the present invention provides compounds according to formula
- each dotted line individually represents an optional double bond, wherein maximally two dotted lines selected from the five dotted lines are a double bond;
- E 1 is independently selected from CR 1 ; and N;
- E 2 is independently selected from NR 2 ; and O;
- E 3 is independently selected from CR 3 ; and N;
- R a is hydrogen or can be taken together with R b to form a substituted or unsubstituted
- R b is hydrogen or can be taken together with R a to form a substituted or unsubstituted
- - Q is independently selected from NR b -C(O); C(O); and C(O)NH; each R 1 , R 3 , R 4 , R 5 and R 6 is independently selected from hydrogen; halogen; -OH; - OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; - NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ; alkyl; alkeny
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally includes one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatoms being selected from the atoms O, S and N;
- each of X 1 Y 1 T 1 W and V is independently selected from -CZ 1 H-; -CZ 1 -; -C-; -N-; NR 101 ; -0-; -S-; or -CO-; wherein at least one of X 1 Y 1 T; W or V is selected from - CZ 1 H- or -CZ 1 - or -C1-; - L is independently selected from being not present; -O-; -NH-; -NR 10 -; Ci- 6 alkenylene; Ci -6 alkynylene;
- each of said Ci -6 alkylene, Ci -6 alkenylene or Ci -6 alkynylene optionally includes one or more heteroatoms, said heteroatoms being selected from the heteroatoms consisting of O 1 S and N 1 and wherein each of said Ci -6 alkylene, Ci- ⁇ slkenylene or can be unsubstituted or substituted;
- B represents a cyclic structure selected from cycloalkyl; cycloalkenyl; cycloalkynyl; aryl; and heterocycle; - m is selected from O; 1 ; 2; 3; 4 and 5;
- R 8 is independently selected from hydrogen; halogen; alkyl; alkenyl; alkynyl; -OH; - OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; - NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ; * wherein said alkyl, alkenyl and alkynyl optionally includes one or more heteroatoms, said heteroatoms being selected from the
- alkyl, alkenyl and alkynyl can be unsubstituted or substituted with Z;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- each R 12 and R 13 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene or heterocycle-alkynylene;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- R 12 and R 13 can be taken together in order to form a (5-, 6-, or 7- membered) heterocycle which can be unsubstituted or substituted; and isomers (in particular stereoisomers, enantiomers or tautomers), solvates, hydrates, salts (in particular pharmaceutically acceptable salts) or prodrugs thereof.
- the compounds have a structure according to the formulae (BB2), (BB3), (BB4), (BB5), (BB6), or (BB7),
- each of X, Y, T, W and V is independently selected from -CZ 1 H-; -CZ 1 -; -C-; -N-; NR 101 ; -O-; -S-; or -CO-; and form with the dotted lines one of the cycles having one of the structural formula (Ib), (lib), (NIb), (IVb), or (Vb).
- the invention provides the compounds of formulae (BB1 ), (BB2), (BB3), (BB4), (BB5), (BB6) and (BB7) and embodiments thereof described herein for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic ⁇ -synuclein amyloidogenesis.
- the invention also provides for pharmaceutical compositions of the compounds of the formulae (BB1 ), (BB2), (BB3), (BB4), (BB5), (BB6) and (BB7) and embodiments thereof described herein and methods for the treatment or prevention of neurodegenerative disorders by using said compounds of the formulae (BB1 ), (BB2), (BB3), (BB4), (BB5), (BB6) and (BB7) and embodiments thereof.
- Another aspect of the present invention provides compounds according to formula (CC1 ), wherein,
- each dotted line individually represents an optional double bond, wherein maximally two dotted lines selected from the five dotted lines are a double bond;
- each of G 1 , G 2 , G 3 and G 4 is independently selected from N; NR c3 ; O; CHR c3 ; and CR c3 ; wherein at least two of G 1 , G 2 , G 3 and G 4 are selected from N; NR c3 ; and O; while the other two of G 1 , G 2 , G 3 and G 4 are selected from CH R c3 ; and CR c3 ;
- each R c3 is selected from hydrogen; and alkyl;
- - R 5 is independently selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; -S(O) 2 R 11 ;
- -SO 2 NR 12 R 13 trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; -NHS(O) 2 R 10 ; - NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle- alkenylene; heterocycle-alkynylene;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally includes one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatoms being selected from the atoms O, S and N;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene can be unsubstituted or substituted with Z;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- each R 12 and R 13 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene or heterocycle-alkynylene;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- R 12 and R 13 can be taken together in order to form a (5-, 6-, or 7- membered) heterocycle which can be unsubstituted or substituted; - each of R 1c and R 2c is independently selected from hydrogen; halogen; alkyl; alkenyl or alkynyl; and isomers (in particular stereoisomers, enantiomers or tautomers), solvates, hydrates, salts (in particular pharmaceutically acceptable salts) or prodrugs thereof.
- each of G 1 , G 2 , G 3 and G 4 is independently selected from N; NR c3 ; O; CH R c3 ; and CR c3 ; and form with the dotted lines one of the cycles having one of the structural formula (Ic), (lie), (NIc), (IVc), or (Vc):
- a particular embodiment of this aspect of the present invention provides compounds according to formula (CC2),
- - R 5 is independently selected from halogen; -OH; -OR 10 ; -SH; -SR 10 ; -S(O)R 11 ; - S(O) 2 R 11 ; -SO 2 NR 12 R 13 ; trifluoromethyl; trifluoromethoxy; nitro; -NHC(O)R 10 ; - NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; -NR 10 C(O)NR 12 R 13 ; - NR 12 R 13 ; -cyano; -COOH; -COOR 10 ; -C(O)NR 12 R 13 ; -C(O)R 11 ; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally includes one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatoms being selected from the atoms O, S and N;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene can be unsubstituted or substituted with Z;
- E is selected from hydrogen; halogen; -OH; -OR 10 ; -SH; -SR 10 ; trifluoromethoxy; - NHC(O)R 10 ; -NHS(O) 2 R 10 ; -NHC(O)NR 12 R 13 ; -NR 10 C(O)R 10 ; -NR 10 S(O) 2 R 10 ; - NR 10 C(O)NR 12 R 13 ; -NR 12 R 13 ; - each R 10 is independently selected from alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle- alkenylene or heterocycle-alkynylene;
- alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N;
- each R 12 and R 13 is independently selected from hydrogen; alkyl; alkenyl; alkynyl; aryl; heterocycle; arylalkylene; arylalkenylene; arylalkynylene; heterocycle-alkylene; heterocycle-alkenylene or heterocycle-alkynylene; *and wherein said alkyl, alkenyl, alkynyl, aryl, heterocycle, arylalkylene, arylalkenylene, arylalkynylene, heterocycle-alkylene, heterocycle-alkenylene or heterocycle-alkynylene optionally include one or more heteroatoms in the alkyl(ene), alkenyl(ene) or alkynyl(ene) moiety, said heteroatom selected from O, S and N; *and wherein a carbon atom or heteroatom of said alkyl, alkenyl, alkyn
- R 12 and R 13 can be taken together in order to form a (5-, 6-, or 7- membered) heterocycle which can be unsubstituted or substituted;
- each of R 1c and R 2c is independently selected from hydrogen; halogen; alkyl; alkenyl or alkynyl; and isomers (in particular stereoisomers, enantiomers or tautomers), solvates, hydrates, salts (in particular pharmaceutically acceptable salts) or prodrugs thereof.
- E is selected from hydrogen; -OH; -NR 12 R 13 (preferably NH 2 , NHMe, N(Me) 2 , NHethyl or N(ethyl) 2 ); -O- alkyl; NHC(O)O-alkyl.
- each of R 1c and R 2c is independently selected from hydrogen; halogen; or alkyl; yet more particularly is hydrogen.
- R 5 is selected from hydrogen, halogen and alkyl (more preferably Ci -6 alkyl, yet more preferably methyl).
- the invention provides the compounds of formulae
- CC1 and (CC2) and embodiments thereof described herein for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic ⁇ - synuclein amyloidogenesis.
- the invention also provides for pharmaceutical compositions of the compounds of the formulae (CC1 ) and (CC2) and embodiments thereof described herein and methods for the treatment or prevention of neurodegenerative disorders by using said compounds of the formulae (CC1 ) and (CC2) and embodiments thereof.
- the invention provides the compounds described herein for use as a medicine for the prevention or treatment of neurodegenerative disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic ⁇ -synuclein amyloidogenesis.
- the invention also provides for pharmaceutical compositions of the compounds described herein and methods for the treatment or prevention of neurodegenerative disorders.
- Tauopathy refers to a disease characterised by dysfunctioning of the TAU protein, for instance manifested by insoluble aggregates or polymers of said protein.
- diseases include, but are not limited to, Alzheimer's disease, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, frontotemporal dementia and parkinsonism (linked to chromosome 17, FTDP-17).
- ⁇ -synucleopathy refers to a disease characterised by the presence of pathological deposition of insoluble ⁇ -synuclein polymers or aggregates intracellular ⁇ / and/or extracellularly.
- diseases include, but are not limited to, Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, and multiple system atrophy.
- neurodegenerative disorders refers to tauopathy and ⁇ -synucleopathy, and thereby includes, but is not limited to Alzheimer's disease, Pick's disease, corticobasal degeneration, progressive supranuclear palsy, frontotemporal dementia, parkinsonism (linked to chromosome 17, FTDP-17), Parkinson's disease, diffuse Lewy body disease, traumatic brain injury, amyotrophic lateral sclerosis, Niemann-Pick disease, Hallervorden-Spatz syndrome, Down syndrome, neuroaxonal dystrophy, and multiple system atrophy.
- Parkinson's disease refers to a chronic progressive nervous disease characterised by neurodegeneration, especially degeneration of dopaminergic neurons. Symptoms include stooped posture, resting tremor, weakness of resting muscles, a shuffling gait, speech impediments, movement difficulties and an eventual slowing of mental processes and dementia.
- Alzheimer disease also called Alzheimer disease, Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer's refers to a chronic progressive nervous disease characterised by neurodegeneration with as most important (early) symptom being memory loss. As the disease advances, symptoms include confusion, irritability and aggression, mood swings, language breakdown, long-term memory loss, and the general withdrawal of the sufferer as their senses decline.
- neuroprotective agent refers to drugs or chemical agents intended to prevent neurodegeneration, including drugs that slow down or stop the progression of neuronal degeneration.
- the present invention relates to a group of novel compounds which have desirable biological properties such as an inhibitory effect on TAU-instigated cytotoxicity. Based on this inhibitory activity, and the fact that these compounds are not toxic to neural cells, these derivatives are useful in the manufacture of a medicament for the prevention and/or treatment of a tauopathy.
- the novel compounds have a structure according to formulae and embodiments thereof as described herein.
- pharmaceutically acceptable carrier or “pharmaceutically acceptable excipient” as used herein in relation to pharmaceutical compositions and combined preparations means any material or substance with which the active principle may be formulated in order to facilitate its application or dissemination to the locus to be treated, for instance by dissolving, dispersing or diffusing the said composition, and / or to facilitate its storage, transport or handling without impairing its effectiveness.
- the pharmaceutically acceptable carrier may be a solid or a liquid or a gas which has been compressed to form a liquid, i.e. the compositions of this invention can suitably be used as concentrates, emulsions, solutions, granulates, dusts, sprays, aerosols, pellets or powders.
- Suitable pharmaceutical carriers for use in the said pharmaceutical compositions and their formulation are well known to those skilled in the art. There is no particular restriction to their selection within the present invention although, due to the usually low or very low water-solubility of the derivatives of this invention, special attention will be paid to the selection of suitable carrier combinations that can assist in properly formulating them in view of the expected time release profile.
- Suitable pharmaceutical carriers include additives such as wetting agents, dispersing agents, stickers, adhesives, emulsifying or surface-active agents, thickening agents, complexing agents, gelling agents, solvents, coatings, antibacterial and antifungal agents (for example phenol, sorbic acid, chlorobutanol), isotonic agents (such as sugars or sodium chloride) and the like, provided the same are consistent with pharmaceutical practice, i.e. carriers and additives which do not create permanent damage to mammals.
- additives such as wetting agents, dispersing agents, stickers, adhesives, emulsifying or surface-active agents, thickening agents, complexing agents, gelling agents, solvents, coatings, antibacterial and antifungal agents (for example phenol, sorbic acid, chlorobutanol), isotonic agents (such as sugars or sodium chloride) and the like, provided the same are consistent with pharmaceutical practice, i.e. carriers and additives which do not create permanent damage to mammals.
- compositions of the present invention may be prepared in any known manner, for instance by homogeneously mixing, dissolving, spray-drying, coating and/or grinding the active ingredients, in a one-step or a multi-steps procedure, with the selected carrier material and, where appropriate, the other additives such as surface- active agents, may also be prepared by micronisation, for instance in view to obtain them in the form of microspheres usually having a diameter of about 1 to 10 ⁇ m, namely for the manufacture of microcapsules for controlled or sustained release of the biologically active ingredient(s).
- novel compounds of the invention can be prepared by the following methods which are exemplified further in the examples.
- the compounds of the invention can be prepared while using a series of chemical reactions well known to those skilled in the art, altogether making up the process for preparing said compounds and exemplified further.
- the processes described further are only meant as examples and by no means are meant to limit the scope of the present invention.
- Compounds of general formula III can be prepared by reacting a compound of general formula I (commercially available or synthesized by procedures known to the skilled in the art or as set forth in the examples below) with a compound of general formula Il in the presence of coupling agent (e.g., thionyl chloride, DCC , EDCI, HATU, PyBop,...) following standard procedures that are known to the skilled in the art or as set forth in the examples below.
- Compounds of general formula III can also be prepared from intermediates with general formula Vl and a suitable precursor of intermediate with general formula V by procedures known to the skilled in the art or as set forth in the examples below. The preparation of intermediates with general formula Il and IV are described hereunder. Scheme 3:
- intermediates XII can be obtained by reacting intermediates VII (commercially available or synthesized by procedures known to the skilled in the art or as set forth in the examples below) wherein R is an ester protecting group such as methyl or ethyl with intermediates of general formula Xl (commercially available or synthesized by procedures known to the skilled in the art or as set forth in the examples below) in the presence of a base (e.g., DABCO, NaHCO 3 , ...) at a temperature raising from room temperature to 90 0 C, in a polar protic and/or aprotic solvent (e.g., EtOH, H 2 O, ethyl acetate, ).
- a base e.g., DABCO, NaHCO 3 , .
- intermediates with general formula XII can also be prepared from intermediates VII and an intermediates of general formula XIII in the presence of a base (e.g., DABCO, NaHCO 3 , ...) at a temperature raising from room temperature to 90 0 C, in a polar protic and/or aprotic solvent (e.g., EtOH, H 2 O, ethyl acetate, ...) to furnish new intermediates of general formula XIV.
- a base e.g., DABCO, NaHCO 3 , ...) at a temperature raising from room temperature to 90 0 C
- a polar protic and/or aprotic solvent e.g., EtOH, H 2 O, ethyl acetate, .
- ester protecting group R is hydrolyzed under standard basic conditions and the intermediates of formula XX are reacted with intermediates I following procedures that are known to the skilled in the art or as set forth in the examples below, provides the desired compounds of formula XXI.
- ester protecting group R is hydrolyzed under standard basic conditions and the intermediates of formula XXIV are reacted with intermediates I following procedures that are known to the skilled in the art or as set forth in the examples below to provide the desired compounds of formula XXV.
- ester protecting group R is hydrolyzed under standard basic conditions and intermediates of formula XXIX are reacted with intermediates I following procedures that are known to the skilled in the art or as set forth in the examples below to provide the desired compounds of formula XXX.
- ester protecting group R is hydrolyzed under standard basic conditions and the intermediates of formula XXXIV are reacted with intermediates I following procedures that are known to the skilled in the art or as set forth in the examples below to provide intermediates of formula XXXV.
- Intermediates XXXV are then subjected to dehydration condition (e.g., burgess reagent; see J. Med. Chem., 51 (7), 2321-25, 2008) in order to obtain the desired compounds of general formula XXXVI.
- Intermediates of formula LIII are converted into intermediates of formula LV wherein R is an ester protecting group such as methyl or ethyl under standard esterification procedures known to the skilled in the art or as set forth in the examples below.
- the lactam function from intermediates LV is then reduced in the presence of 9- borabicyclo[3.3.1]nonane (9-BBN) in a polar aprotic solvent (e.g., THF) at a temperature raising from RT to 65°C (most preferably 65°C) in order to obtain the desired intermediates LVI.
- a polar aprotic solvent e.g., THF
- intermediates LX are subsequently reacted with intermediates of formula LXI (commercially available or synthesized by procedures known to the skilled in the art or as set forth in the examples below) in order to obtain the desired compounds with formula LXII.
- intermediates LXI can be activated by treatment with a strong base (most preferably NaH) in a polar aprotic solvent (e.g., THF, DMF, ...) at a temperature raising from 0 0 C to RT, in order to enhance the reactivity of the amine.
- ester protecting group R is hydrolyzed under standard basic conditions and intermediates of formula LXIV are converted in intermediates of general formula LXV. These intermediates are reacted with hydrazide derivatives of formula LXVI (commercially available or synthesized by procedures known to the skilled in the art or as set forth in the examples below) in a polar aprotic solvent (e.g. dichloromethane, THF, DMF%) in the presence of a base (e.g.
- Part A represents the preparation of the compounds (intermediates and final compounds) whereas Part B represents the pharmacological examples.
- the separations were performed with a X-Bridge Prep C18, 100x19mm, 5 ⁇ m column equipped with a X-Bridge C18, 5 ⁇ m, 19x10mm Guard column.
- Solvent A Ammonium Acetate puriss p. a. for HPLC 1 OmM in milliQ water, adjusted at pH10 with ammonium hydroxide puriss p. a. for HPLC.
- Solvent B acetonitrile HPLC grade.
- Solvent A Formic Acid LC-MS grade 0.1 % in milliQ water
- Solvent B Acetonitrile HPLC grade.
- Solvent A Ammonium Acetate puriss p. a. for HPLC 1OmM in milliQ water, adjusted at pH10 with Ammonium Hydroxyde puriss p. a. for HPLC.
- Solvent B Acetonitrile HPLC grade.
- Solvent A Formic Acid LC-MS grade 0.1 % in milliQ water
- Solvent B Formic Acid LC-MS grade 0.1% in Acetonitrile HPLC grade.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17157306.6A EP3190109B1 (fr) | 2009-06-11 | 2010-06-11 | Dérivés d'indolamide et composés associés destinés à être utilisés dans le traitement des maladies neurodégénératives |
SI201031435A SI2440550T1 (sl) | 2009-06-11 | 2010-06-11 | Indolamidni derivati in povezane spojine za uporabo pri zdravljenju neurodegenerativnih bolezni |
HRP20170731TT HRP20170731T1 (hr) | 2009-06-11 | 2017-05-16 | Derivati indol amida i srodni spojevi za uporabu za liječenje neurodegenerativnih bolesti |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0910003.3A GB0910003D0 (en) | 2009-06-11 | 2009-06-11 | Novel compounds for the treatment of neurodegenerative diseases |
PCT/EP2010/058271 WO2010142801A1 (fr) | 2009-06-11 | 2010-06-11 | Dérivés d'indolamide et composés associés destinés à être utilisés dans le traitement des maladies neurodégénératives |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17157306.6A Division EP3190109B1 (fr) | 2009-06-11 | 2010-06-11 | Dérivés d'indolamide et composés associés destinés à être utilisés dans le traitement des maladies neurodégénératives |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2440550A1 true EP2440550A1 (fr) | 2012-04-18 |
EP2440550B1 EP2440550B1 (fr) | 2017-03-15 |
Family
ID=40937200
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17157306.6A Active EP3190109B1 (fr) | 2009-06-11 | 2010-06-11 | Dérivés d'indolamide et composés associés destinés à être utilisés dans le traitement des maladies neurodégénératives |
EP10728150.3A Active EP2440550B1 (fr) | 2009-06-11 | 2010-06-11 | Dérivés d'indolamide et composés associés destinés à être utilisés dans le traitement des maladies neurodégénératives |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17157306.6A Active EP3190109B1 (fr) | 2009-06-11 | 2010-06-11 | Dérivés d'indolamide et composés associés destinés à être utilisés dans le traitement des maladies neurodégénératives |
Country Status (13)
Country | Link |
---|---|
US (4) | US8618138B2 (fr) |
EP (2) | EP3190109B1 (fr) |
JP (1) | JP6116245B2 (fr) |
CN (1) | CN102803252B (fr) |
AU (1) | AU2010258566B2 (fr) |
CA (1) | CA2765181C (fr) |
EA (1) | EA025086B9 (fr) |
ES (1) | ES2627957T3 (fr) |
GB (1) | GB0910003D0 (fr) |
HR (1) | HRP20170731T1 (fr) |
HU (1) | HUE034733T2 (fr) |
SI (1) | SI2440550T1 (fr) |
WO (1) | WO2010142801A1 (fr) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
CA2777782C (fr) * | 2009-10-15 | 2016-06-28 | Children's Medical Center Corporation | Inhibiteurs de sepiapterine reductase pour le traitement de la douleur |
WO2011084642A1 (fr) | 2009-12-16 | 2011-07-14 | Neuropore Therapies, Inc. | Composé approprié pour le traitement de synucléopathies |
GB201021103D0 (en) * | 2010-12-13 | 2011-01-26 | Univ Leuven Kath | New compounds for the treatment of neurodegenerative diseases |
WO2012088266A2 (fr) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3 |
AR086113A1 (es) | 2011-04-30 | 2013-11-20 | Abbott Lab | Isoxazolinas como agentes terapeuticos |
GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
WO2013111108A1 (fr) * | 2012-01-27 | 2013-08-01 | Novartis Ag | Dérivés hétéroarylcarboxamide à 5 chaînons comme inhibiteurs de la kallikréine plasmatique |
AU2013205306B2 (en) | 2012-03-16 | 2015-09-17 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
EP2666766A1 (fr) | 2012-05-21 | 2013-11-27 | Dr. August Wolff GmbH & Co. KG Arzneimittel | Nouveaux composés E, E-diène et leur utilisation en tant que médicaments et produits cosmétiques |
PT3495367T (pt) | 2012-06-13 | 2020-11-12 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
BR112015001096A2 (pt) * | 2012-07-16 | 2017-06-27 | Neuropore Therapies Inc | derivados de di e tri-heteroaril como inibidores de agregação de proteína |
WO2014026125A1 (fr) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Dérivés de pyrazine en tant qu'inhibiteurs de fgfr |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
ES2670517T3 (es) * | 2013-01-30 | 2018-05-30 | Sumitomo Chemical Company, Limited | Compuesto de amida, un agente de control de plagas de artrópodos y un método para controlar las plagas de artrópodos |
TWI715901B (zh) | 2013-04-19 | 2021-01-11 | 美商英塞特控股公司 | 作為fgfr抑制劑之雙環雜環 |
RU2712621C2 (ru) | 2013-05-23 | 2020-01-30 | Калвиста Фармасьютикалз Лимитед | Азотсодержащие гетероциклические производные, полезные в качестве ингибитора калликреина плазмы |
WO2015022546A1 (fr) | 2013-08-14 | 2015-02-19 | Kalvista Pharmaceuticals Limited | Inhibiteurs de la kallicréine plasmatique |
TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
DK3348556T3 (da) * | 2014-01-29 | 2020-08-03 | UCB Biopharma SRL | Heteroarylamider som hæmmere af proteinaggregering |
JP6577479B2 (ja) * | 2014-02-27 | 2019-09-18 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Nav チャンネル阻害剤としてのヘテロ環化合物及びその使用 |
CA2942387A1 (fr) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Composes, compositions et procedes pour augmenter l'activite cftr |
WO2015138909A1 (fr) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Composés, compositions et procédés pour augmenter l'activité du cftr |
WO2015143300A1 (fr) | 2014-03-21 | 2015-09-24 | The Board Of Regents Of The University Of Texas System | Traitements à base d'isoxazole pour la démence fronto-temporale |
CA2952862A1 (fr) | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Composes, compositions et procedes pour augmenter l'activite du cftr |
MA40759A (fr) | 2014-09-26 | 2017-08-01 | Pfizer | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
US10344023B2 (en) | 2014-12-23 | 2019-07-09 | Proteostasis Therapeutics, Inc. | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
CA2971855A1 (fr) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derives d'amide 5-(hetero)arylpyrazol-3-carboxylique ou d'amide 1-(hetero)aryltriazol-4-carboxylique utiles pour le traitement, entre autres, de la fibrose kystique |
MA41253A (fr) * | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
AU2015369690B2 (en) | 2014-12-23 | 2019-01-17 | SMA Therapeutics Inc. | 3,5-diaminopyrazole kinase inhibitors |
US10392378B2 (en) | 2014-12-23 | 2019-08-27 | Proteostasis Therapeutics, Inc. | Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
WO2016134294A1 (fr) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
CN113004278B (zh) | 2015-02-20 | 2023-07-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
LT3307734T (lt) | 2015-06-09 | 2020-05-11 | Abbvie Inc. | Branduolinio receptoriaus moduliatoriai (ror), skirti uždegiminių ir autoimuninių ligų gydymui |
AU2016297886B2 (en) | 2015-07-24 | 2020-12-10 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing CFTR activity |
US10975066B2 (en) | 2015-07-29 | 2021-04-13 | UCB Biopharma SRL | Bis-heteroaryl derivatives as modulators of protein aggregation |
JO3633B1 (ar) * | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JP6929276B2 (ja) | 2015-10-06 | 2021-09-01 | プロテオステイシス セラピューティクス,インコーポレイテッド | 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物 |
MA44498A (fr) | 2016-03-31 | 2019-02-06 | Janssen Pharmaceuticals Inc | Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue |
SG11201808138YA (en) | 2016-03-31 | 2018-10-30 | Janssen Pharmaceuticals Inc | Substituted indole derivatives as dengue viral replication inhibitors |
JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
EA201892200A1 (ru) | 2016-04-01 | 2019-03-29 | Янссен Фармасьютикалз, Инк. | Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге |
KR102448404B1 (ko) | 2016-04-07 | 2022-09-27 | 프로테오스타시스 테라퓨틱스, 인크. | 규소 원자 함유 이바카프터 유사체 |
RS60600B1 (sr) | 2016-05-31 | 2020-08-31 | Kalvista Pharmaceuticals Ltd | Derivati pirazola kao inhibitori kalikreina plazme |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
US10899751B2 (en) | 2016-06-21 | 2021-01-26 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing CFTR activity |
US10889584B2 (en) * | 2017-01-26 | 2021-01-12 | UCB Biopharma SRL | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation |
KR20190112031A (ko) | 2017-01-26 | 2019-10-02 | 유씨비 바이오파마 에스피알엘 | 단백질 응집의 조절제로서의 알콕시 비스-헤테로아릴 유도체 |
ES2882285T3 (es) | 2017-01-26 | 2021-12-01 | Ucb Biopharma Sprl | Derivados de bis-heteroarilo como moduladores de la agregación de proteínas |
JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
EP3395803A1 (fr) | 2017-04-28 | 2018-10-31 | Institut Pasteur | Dérivés d'imidazopyrazine, leur procédé de préparation et leurs utilisations comme luciférines |
PL3621963T3 (pl) * | 2017-05-11 | 2024-05-20 | Remynd N.V. | Związki do leczenia epilepsji, zaburzeń neurodegeneracyjnych i innych zaburzeń oun |
WO2018206757A1 (fr) | 2017-05-11 | 2018-11-15 | Remynd N.V. | Inhibiteurs de pde6delta destinés à être utilisés dans la prévention et/ou le traitement de l'épilepsie et/ou de troubles neurodégénératifs |
US11407715B2 (en) | 2017-05-22 | 2022-08-09 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
KR102625991B1 (ko) | 2017-05-22 | 2024-01-16 | 얀센 파마슈티칼즈, 인코포레이티드 | 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
EP3689870B1 (fr) | 2017-09-27 | 2022-07-13 | Kagoshima University | Médicament analgésique utilisant un médicament antagoniste du récepteur pac1 |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
RU2020121151A (ru) | 2017-11-29 | 2021-12-29 | Калвиста Фармасьютикалз Лимитед | Дозированные формы, содержащие ингибитор плазменного калликреина |
EA202092094A1 (ru) | 2018-03-05 | 2020-12-10 | Бристол-Маерс Сквибб Компани | Фенилпирролидиноновые агонисты формилпептидного рецептора 2 |
WO2019213544A2 (fr) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation |
CR20200591A (es) | 2018-05-04 | 2021-03-31 | Incyte Corp | Sales de un inhibidor de fgfr |
CN113490668A (zh) | 2018-10-05 | 2021-10-08 | 安娜普尔纳生物股份有限公司 | 用于治疗与apj受体活性有关的疾病的化合物和组合物 |
US10689360B1 (en) * | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
EP3932490A4 (fr) | 2019-02-27 | 2022-11-16 | Kagoshima University | Agent antiprurigineux utilisant un antagoniste du récepteur pac1 |
WO2020185532A1 (fr) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr |
WO2021007269A1 (fr) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr |
WO2021023858A1 (fr) * | 2019-08-08 | 2021-02-11 | Université De Strasbourg | Modulateurs allostériques positifs au trkb |
WO2021028645A1 (fr) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Inhibiteurs de la kallicréine plasmatique |
CN112480100B (zh) * | 2019-09-11 | 2022-10-14 | 康威(广州)生物科技有限公司 | 吡咯烷酮衍生物 |
EP4025212A4 (fr) * | 2019-09-27 | 2023-08-23 | Collaborations Pharmaceuticals, Inc. | Dérivés d'isoxazole-3-carboxamide et leur utilisation pour le traitement de maladies provoquées par une infection virale |
TW202128685A (zh) | 2019-10-14 | 2021-08-01 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
TW202132281A (zh) | 2019-11-06 | 2021-09-01 | 南韓商柳韓洋行股份有限公司 | 吡咯啶及哌啶類化合物 |
CA3162010A1 (fr) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derives d'un inhibiteur de fgfr |
EP4069696A1 (fr) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr |
GB2591730A (en) | 2019-12-09 | 2021-08-11 | Kalvista Pharmaceuticals Ltd | New polymorphs |
WO2021141041A1 (fr) * | 2020-01-07 | 2021-07-15 | 大日本住友製薬株式会社 | Agent thérapeutique pour tauopathies |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
EP4100023A4 (fr) * | 2020-02-07 | 2024-03-13 | University of South Florida | Inhibition de l'oligomérisation de la bêta-arrestine en tauopathie |
EP4147701A4 (fr) | 2020-05-08 | 2024-06-12 | Kagoshima University | Médicament antidépresseur/anxiolytique utilisant un antagoniste du récepteur du pac1 |
TW202228686A (zh) | 2020-10-15 | 2022-08-01 | 英商卡爾維斯塔製藥有限公司 | 血管性水腫之治療 |
US20230381162A1 (en) | 2020-10-23 | 2023-11-30 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
CA3220274A1 (fr) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Heterocycles tricycliques en tant qu'inhibiteurs de fgfr |
WO2023002219A1 (fr) | 2021-07-23 | 2023-01-26 | Kalvista Pharmaceuticals Limited | Traitements de l'angio-oedème héréditaire |
WO2023209381A1 (fr) | 2022-04-27 | 2023-11-02 | Kalvista Pharmaceuticals Limited | Formulations d'un inhibiteur de la kallicréine plasmatique |
CN115974862B (zh) * | 2023-01-30 | 2024-04-19 | 四川大学华西医院 | 一种基于protac原理的hl化合物及其制备方法和应用 |
KR102657677B1 (ko) * | 2023-10-26 | 2024-04-16 | 국방과학연구소 | 공융용매 하에서 흐름반응을 이용한 아이소옥사졸의 제조 방법 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0287237A (ja) * | 1988-09-22 | 1990-03-28 | Fujitsu Ltd | Execute命令制御方式 |
US5202344A (en) | 1990-12-11 | 1993-04-13 | G. D. Searle & Co. | N-substituted lactams useful as cholecystokinin antagonists |
US5416193A (en) * | 1993-04-30 | 1995-05-16 | Pfizer Inc. | Coupling reagent and method |
JPH0987237A (ja) * | 1995-09-21 | 1997-03-31 | Kyowa Hakko Kogyo Co Ltd | 芳香族誘導体 |
US7101878B1 (en) * | 1998-08-20 | 2006-09-05 | Agouron Pharmaceuticals, Inc. | Non-peptide GNRH agents, methods and intermediates for their preparation |
TW200404789A (en) * | 1999-03-15 | 2004-04-01 | Axys Pharm Inc | Novel compounds and compositions as protease inhibitors |
GB0017676D0 (en) * | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
US7259141B2 (en) * | 2001-03-30 | 2007-08-21 | Wisconsin Alumni Research Foundation | Vancomycin analogs and methods thereof |
EP1689729A1 (fr) * | 2003-11-28 | 2006-08-16 | F. Hoffmann-La Roche AG | Acide tetronique et tetramic en tant qu'inhibiteurs de la beta-secretase |
WO2005062851A2 (fr) * | 2003-12-22 | 2005-07-14 | Pappolla Miguel A | Indole-3-propionamide et ses derives |
TW200602314A (en) * | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
CN1960970A (zh) * | 2004-05-28 | 2007-05-09 | 田边制药株式会社 | 作为cb1受体的拮抗剂的吡咯烷衍生物 |
WO2006007542A1 (fr) | 2004-07-01 | 2006-01-19 | The Regents Of The University Of California | Inhibition de petites molécules d'interaction dans le domaine des protéines pdz |
JP2008007405A (ja) | 2004-12-07 | 2008-01-17 | Takeda Chem Ind Ltd | カルボキサミド誘導体 |
CN101223155A (zh) * | 2005-07-12 | 2008-07-16 | 拜尔农科股份有限公司 | 苯并杂环基乙基羧酰胺衍生物 |
JP2007194232A (ja) | 2006-01-17 | 2007-08-02 | Shin Etsu Handotai Co Ltd | シリコン単結晶ウエーハの製造方法 |
AU2007275301A1 (en) * | 2006-07-20 | 2008-01-24 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1 |
US7998995B2 (en) * | 2006-12-08 | 2011-08-16 | Exelixis Patent Company Llc | LXR and FXR modulators |
US20080227823A1 (en) * | 2007-03-12 | 2008-09-18 | Hassan Pajouhesh | Amide derivatives as calcium channel blockers |
EP2002834A1 (fr) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Aryle/hétarylamides en tant que modulateurs du récepteur EP2 |
EP2167497A2 (fr) | 2007-06-29 | 2010-03-31 | Sunesis Pharmaceuticals, Inc. | Composés hétérocycliques utiles en tant qu'inhibiteurs de la kinase raf |
AU2008300631A1 (en) | 2007-09-20 | 2009-03-26 | Abbott Healthcare Products B.V. | 5-aryl-4,5-dihydro-(1H)-pyrazoles as cannabinoid CB1 |
GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
-
2009
- 2009-06-11 GB GBGB0910003.3A patent/GB0910003D0/en not_active Ceased
-
2010
- 2010-06-11 US US13/377,505 patent/US8618138B2/en active Active
- 2010-06-11 EP EP17157306.6A patent/EP3190109B1/fr active Active
- 2010-06-11 HU HUE10728150A patent/HUE034733T2/en unknown
- 2010-06-11 SI SI201031435A patent/SI2440550T1/sl unknown
- 2010-06-11 EA EA201200002A patent/EA025086B9/ru not_active IP Right Cessation
- 2010-06-11 JP JP2012514489A patent/JP6116245B2/ja active Active
- 2010-06-11 AU AU2010258566A patent/AU2010258566B2/en active Active
- 2010-06-11 CN CN201080025999.5A patent/CN102803252B/zh active Active
- 2010-06-11 CA CA2765181A patent/CA2765181C/fr active Active
- 2010-06-11 WO PCT/EP2010/058271 patent/WO2010142801A1/fr active Application Filing
- 2010-06-11 EP EP10728150.3A patent/EP2440550B1/fr active Active
- 2010-06-11 ES ES10728150.3T patent/ES2627957T3/es active Active
-
2013
- 2013-10-22 US US14/060,563 patent/US9434722B2/en active Active
-
2016
- 2016-07-21 US US15/215,750 patent/US10117850B2/en active Active
-
2017
- 2017-05-16 HR HRP20170731TT patent/HRP20170731T1/hr unknown
-
2018
- 2018-09-19 US US16/135,593 patent/US20190054068A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2010142801A1 * |
Also Published As
Publication number | Publication date |
---|---|
US20140066457A1 (en) | 2014-03-06 |
EA025086B9 (ru) | 2017-01-30 |
EA201200002A1 (ru) | 2012-05-30 |
CN102803252B (zh) | 2016-05-25 |
CA2765181C (fr) | 2017-04-04 |
GB0910003D0 (en) | 2009-07-22 |
CN102803252A (zh) | 2012-11-28 |
US8618138B2 (en) | 2013-12-31 |
US20160324828A1 (en) | 2016-11-10 |
JP2012529476A (ja) | 2012-11-22 |
CA2765181A1 (fr) | 2010-12-16 |
HRP20170731T1 (hr) | 2017-07-28 |
WO2010142801A1 (fr) | 2010-12-16 |
HUE034733T2 (en) | 2018-02-28 |
US20190054068A1 (en) | 2019-02-21 |
AU2010258566B2 (en) | 2015-05-14 |
EP3190109B1 (fr) | 2020-02-19 |
EP3190109A1 (fr) | 2017-07-12 |
SI2440550T1 (sl) | 2017-05-31 |
US9434722B2 (en) | 2016-09-06 |
EA025086B1 (ru) | 2016-11-30 |
ES2627957T3 (es) | 2017-08-01 |
EP2440550B1 (fr) | 2017-03-15 |
AU2010258566A1 (en) | 2012-01-19 |
US10117850B2 (en) | 2018-11-06 |
US20120083475A1 (en) | 2012-04-05 |
JP6116245B2 (ja) | 2017-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3190109B1 (fr) | Dérivés d'indolamide et composés associés destinés à être utilisés dans le traitement des maladies neurodégénératives | |
ES2462341T3 (es) | Derivados heterocíclicos como inhibidores de histona desacetilasas (HDAC) | |
DK2651888T3 (en) | N - ((1H-indol-3-yl) alkyl) -4-benzyl) benzamide and N - ((1H-pyrrolo [2,3-b] pyridin-3-yl) alkyl) -4-benzyl ) benzamide derivatives as alpha-synuclein aggregation inhibitors for the treatment of neurodegenerative diseases | |
EP2651887B1 (fr) | Dérivés de carboxamide N-(2-(5-substitué-1H-indol-3-yl)éthyl)biphényl-4- et composés similaires en tant qu'inhibiteurs de la toxicité induite par l'aggregation TAU pour le traitement de maladies neuro-dégénératives | |
AU2008262038A1 (en) | 5-heteroaryl substituted indazoles as kinase inhibitors | |
AU2004232981A1 (en) | Indazole derivatives as JNK inhibitors | |
MXPA05006742A (es) | Benzoxazinas y derivados de las mismas como inhibidores de fosfoinositido-3-quinasas. | |
CA2823877A1 (fr) | Nouveaux derives de pyrazole et d'imidazole utiles a titre d'antagonistes d'orexine | |
AU2006283884B2 (en) | (Indol-3-yl)-heterocycle derivatives as agonists of the cannabinoid CB1 receptor | |
JP5011097B2 (ja) | カンナビノイドcb1受容体のアゴニストとしての、(インドール−3−イル)−複素環誘導体 | |
US7763732B2 (en) | Indole derivatives | |
KR101318689B1 (ko) | 칸나비노이드 cb1 수용체 길항제로서 황 함유 피라졸-헤테로사이클 유도체 | |
RU2376302C2 (ru) | Производные (индол-3-ил)гетероциклических соединений в качестве агонистов каннабиноидных рецепторов св1 | |
US20080081815A1 (en) | Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists | |
AU2013231090A1 (en) | 5-heteroaryl substituted indazoles as kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20120110 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1169100 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20130918 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KILONDA, AMURI Inventor name: VAN DOOREN, TOM Inventor name: CHALTIN, PATRICK Inventor name: MARCHAND, ARNAUD Inventor name: ROJAS DE LA PARRA, VERONICA Inventor name: ALLASIA, SARA Inventor name: GRIFFIOEN, GERARD |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160502 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20160915 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: CHALTIN, PATRICK Inventor name: ALLASIA, SARA Inventor name: GRIFFIOEN, GERARD Inventor name: KILONDA, AMURI Inventor name: ROJAS DE LA PARRA, VERONICA Inventor name: MARCHAND, ARNAUD Inventor name: VAN DOOREN, TOM |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: ISLER AND PEDRAZZINI AG, CH |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 875403 Country of ref document: AT Kind code of ref document: T Effective date: 20170415 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602010040760 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: TUEP Ref document number: P20170731 Country of ref document: HR |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20170522 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: T1PR Ref document number: P20170731 Country of ref document: HR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170615 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170315 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170616 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2627957 Country of ref document: ES Kind code of ref document: T3 Effective date: 20170801 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170315 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170615 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170315 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170315 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170315 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170315 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170717 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170715 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170315 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170315 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602010040760 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1169100 Country of ref document: HK |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170315 |
|
26N | No opposition filed |
Effective date: 20171218 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E034733 Country of ref document: HU |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170611 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170611 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20170731 Country of ref document: HR Payment date: 20190530 Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 875403 Country of ref document: AT Kind code of ref document: T Effective date: 20170315 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170315 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170315 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170315 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20170731 Country of ref document: HR Payment date: 20200604 Year of fee payment: 11 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170315 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20170731 Country of ref document: HR Payment date: 20210608 Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20170731 Country of ref document: HR Payment date: 20220608 Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20170731 Country of ref document: HR Payment date: 20230607 Year of fee payment: 14 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230521 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230620 Year of fee payment: 14 Ref country code: IE Payment date: 20230620 Year of fee payment: 14 Ref country code: FR Payment date: 20230627 Year of fee payment: 14 Ref country code: DK Payment date: 20230622 Year of fee payment: 14 Ref country code: DE Payment date: 20230620 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SI Payment date: 20230602 Year of fee payment: 14 Ref country code: SE Payment date: 20230620 Year of fee payment: 14 Ref country code: HU Payment date: 20230622 Year of fee payment: 14 Ref country code: HR Payment date: 20230607 Year of fee payment: 14 Ref country code: FI Payment date: 20230621 Year of fee payment: 14 Ref country code: AT Payment date: 20230621 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20230620 Year of fee payment: 14 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230623 Year of fee payment: 14 Ref country code: GB Payment date: 20230622 Year of fee payment: 14 Ref country code: ES Payment date: 20230829 Year of fee payment: 14 Ref country code: CH Payment date: 20230702 Year of fee payment: 14 |